

DANIEL (DANI) I. COHEN, MPH, PhD

Title: Professor of Epidemiology, School of Public Health, Faculty of Medicine, Tel Aviv University

Email: dancohen@tauex.tau.ac.il

PUBLICATIONS (Peer-Reviewed)

ORIGINAL ARTICLES

1. **Cohen ID**, Rouach TM, Dinari G. Food-borne epidemic of streptococcal pharyngitis at an Israeli military training base. *Mil Med.* 1982;147(4):318-9.
2. **Cohen DI**, Rouach TM, Rogol M. A *Campylobacter* enteritis outbreak in a military base in Israel. *Isr J Med Sci.* 1984;20(3):216-8.
3. **Cohen D**, Green MS, Block C, Rouach T, Ofek I, Swartz T, Lowell G, Tramont E. Assessment of antibody screening in selection of subjects for field trials of *Shigella* vaccines. *Annali Sclavo Collana monografica.* 1986;3(1-2):151-4
4. **Cohen D**, Ferne M, Rouach T, Bergner-Rabinowitz S. Food-borne outbreak of group G streptococcal sore throat in an Israeli military base. *Epidemiol Infect.* 1987;99(2):249-55.
5. Green MS, **Cohen D**, Block C, Rouach Z, Dycian R. A prospective epidemiologic study of shigellosis in the Israel Defense forces: implications for the use of shigella vaccines. *Isr J Med Sci.* 1987;23(7):811-5.
6. **Cohen D**, Green MS, Block C, Rouach T, Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. *J Infect Dis.* 1988;157(5):1068-71.
7. **Cohen D**, Block C, Green MS, Lowell G, Ofek I. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic *Shigella* infections. *J Clin Microbiol.* 1989;27(1):162-7.
8. Ben-Yehuda O, **Cohen D**, Alkan M, Greenbaum A, Jelin N, Steinherz R. Doxycycline prophylaxis for shigellosis. *Archives of internal medicine.* 1990;150(1):209-12.
9. Green MS, **Cohen D**, Slepon R, Handsher R, Zaaide Y, Rannon L, Danon Y. Sociodemographic correlates of neutralizing poliovirus and hepatitis A virus antibodies as markers of different modes of acquiring immunity. *Am J Public Health.* 1990;80(10):1270-1.
10. Green MS, Melnick JL, **Cohen D**, Slepon R, Danon Y. Response to trivalent oral poliovirus vaccine with and without immune serum globulin in young adults in Israel in 1988. *J Infect Dis.* 1990;162(4):971-4.
11. Ozbonfil D, **Cohen D**, Ohad E, Sechter I. An outbreak of enteritis associated with enteroinvasive *E. coli* in an Israeli military base. *Public Health Rev.* 1990;18(2):171-7.
12. Schwartz D, Melamed I, **Cohen D**, Konforti N, Goldhar J. ELISA for *Campylobacter jejuni* antibodies in Israeli children with diarrhea and in healthy soldiers. *Isr J Med Sci.* 1990;26(6):319-24.
13. Sechter I, **Cohen D**. Developing epidemiological markers for *Shigella sonnei*: a proposed phage-typing scheme. *Public Health Rev.* 1990;18(3):261-6.

14. **Cohen D**, Green M, Block C, Slepon R, Ambar R, Wasserman SS, Levine M. Reduction of transmission of shigellosis by control of houseflies (*Musca domestica*). *Lancet*. 1991;337(8748):993-7.
15. **Cohen D**, Green MS, Block C, Slepon R, Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. *J Clin Microbiol*. 1991;29(2):386-9.
16. **Cohen D**, Katzenelson E, Green M, Slepon R, Bercovier H, Danon Y. Prevalence and correlates of diphtheria toxin antibodies among young adults in Israel. *J Infect*. 1991;23(2):117-21.
17. **Cohen D**, Slepon R, Green MS. Sociodemographic factors associated with serum anti-*Shigella* lipopolysaccharide antibodies and shigellosis. *Int J Epidemiol*. 1991;20(2):546-50.
18. Green MS, Block C, **Cohen D**, Slater PE. Four decades of shigellosis in Israel: epidemiology of a growing public health problem. *Rev Infect Dis*. 1991;13(2):248-53.
19. **Cohen D**, Block CS, Ambar R, Shif I, Greenberg Z, Green MS. Pilot study of an extended range of potential etiologic agents of diarrhea in the Israel Defense forces. *Isr J Med Sci*. 1992;28(1):49-51.
20. **Cohen D**, Green MS, Block C, Slepon R, Lerman Y. Natural immunity to shigellosis in two groups with different previous risks of exposure to *Shigella* is only partly expressed by serum antibodies to lipopolysaccharide. *J Infect Dis*. 1992;165(4):785-7.
21. Gillis D, **Cohen D**, Beck A, Rouach T, Katzenelson E, Green M. A new *Streptococcus* group A M-29 variant isolated during a suspected common-source epidemic. *Mil Med*. 1992;157(6):282-3.
22. Lerman Y, **Cohen D**, Gluck A, Ohad E, Sechter I. A cluster of cases of *Escherichia coli* O157 infection in a day-care center in a communal settlement (Kibbutz) in Israel. *J Clin Microbiol*. 1992;30(2):520-1.
23. Levine MM, McEwen J, Losonsky G, Reymann M, Harari I, Brown JE, Taylor DN, Donohue-Rolfe A, **Cohen D**, Bennish M. Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with *Shigella dysenteriae* 1 dysentery. *J Clin Microbiol*. 1992;30(7):1636-41.
24. Orr N, Robin G, Lowell G, **Cohen D**. Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with *Shigella sonnei*. *J Clin Microbiol*. 1992;30(8):2165-8.
25. Shohat T, Heering SL, Slepon R, Vardi D, **Cohen D**, Green M, Lerman Y. Rapid method for mapping morbidity and mortality during epidemics. *Public Health Rev*. 1992;20(3-4):297-302.
26. Yavzori M, **Cohen D**, Bercovier H. Molecular epidemiology of *Shigella* infections in Israel. *Epidemiol Infect*. 1992;109(2):273-82.
27. Green MS, **Cohen D**, Lerman Y, Sjogren M, Binn LN, Zur S, Slepon R, Robin G, Hoke C, Bancroft W. Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin. *J Infect Dis*. 1993;168(3):740-3.

28. Green MS, **Cohen D**, Slepon R, Robin G, Wiener M. Ethnic and gender differences in the prevalence of anti-cytomegalovirus antibodies among young adults in Israel. *Int J Epidemiol.* 1993;22(4):720-3.
29. Green MS, Handsher R, **Cohen D**, Melnick JL, Slepon R, Mendelsohn E, Danon YL. Age differences in immunity against wild and vaccine strains of poliovirus prior to the 1988 outbreak in Israel and response to booster immunization. *Vaccine.* 1993;11(1):75-81.
30. Lerman Y, Riskin-Mashiach S, **Cohen D**, Slepon R, Shohat T, Harari H, Wiener M, Danon YL. Immunity to measles in young adults in Israel. *Infection.* 1993;21(3):154-7.
31. Orr N, Robin G, **Cohen D**, Arnon R, Lowell GH. Immunogenicity and efficacy of oral or intranasal *Shigella flexneri* 2a and *Shigella sonnei* proteosome-lipopolysaccharide vaccines in animal models. *Infect Immun.* 1993;61(6):2390-5.
32. Taylor DN, Trofa AC, Sadoff J, Chu C, Bryla D, Shiloach J, **Cohen D**, Ashkenazi S, Lerman Y, Egan W. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of *Shigella dysenteriae* type 1, *Shigella flexneri* type 2a, and *Shigella sonnei* (*Plesiomonas shigelloides*) bound to bacterial toxoids. *Infect Immun.* 1993;61(9):3678-87.
33. **Cohen D**, Ashkenazi S, Green MS, Yavzori M, Orr N, Slepon R, Lerman Y, Robin G, Ambar R, Block C. Safety and immunogenicity of the oral *E. coli* K12-S. *flexneri* 2a vaccine (EcSf2a-2) among Israeli soldiers. *Vaccine.* 1994;12(15):1436-42.
34. **Cohen D**, Green MS, Katzenelson E, Slepon R, Bercovier H, Wiener M. Long-term persistence of anti-diphtheria toxin antibodies among adults in Israel. Implications for vaccine policy. *Eur J Epidemiol.* 1994;10(3):267-70.
35. Green MS, **Cohen D**, Lerman Y, Sjogren M, Binn LN, Zur S, Slepon R, Robin G, Hoke C, Bancroft W. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine. *Isr J Med Sci.* 1994;30(5-6):485-8.
36. Green MS, Handsher R, Slepon R, Ashkenazi S, Mendelson E, **Cohen D**. Four-year follow-up of the immune status of young adults given a single booster dose of trivalent oral poliovaccine. *Vaccine.* 1994;12(7):582-4.
37. Green MS, Shohat T, Lerman Y, **Cohen D**, Slepon R, Duvdevani P, Varsano N, Dagan R, Mendelson E. Sex differences in the humoral antibody response to live measles vaccine in young adults. *Int J Epidemiol.* 1994;23(5):1078-81.
38. Lerman Y, Slepon R, **Cohen D**. Epidemiology of acute diarrheal diseases in children in a high standard of living rural settlement in Israel. *Pediatr Infect Dis J.* 1994;13(2):116-22.
39. Lerman Y, Yavzori M, Ambar R, Sechter I, Wiener M, **Cohen D**. Epidemic spread of *Shigella sonnei* shigellosis and evidence for development of immunity among children attending day-care centers in a communal settlement (Kibbutz). *J Clin Microbiol.* 1994;32(4):1092-4.
40. Nahum E, Lerman Y, **Cohen D**, Salpon R, Danon YL. The immune response to booster vaccination against diphtheria toxin at age 18-21 years. *Isr J Med Sci.* 1994;30(8):600-3.
41. Olsha M, Mendelson E, Shohat T, **Cohen D**, Duvdevani P, Lerman Y, Danon YL. Measles immunity in Israeli young adults: effects of second immunization at 18 years of age. *Isr J Med Sci.* 1994;30(8):596-9.

42. Orr N, Arnon R, Rubin G, **Cohen D**, Bercovier H, Lowell GH. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines. *Infect Immun.* 1994;62(11):5198-200.
43. Yavzori M, **Cohen D**, Wasserlauf R, Ambar R, Rechavi G, Ashkenazi S. Identification of Shigella species in stool specimens by DNA amplification of different loci of the Shigella virulence plasmid. *Eur J Clin Microbiol Infect Dis.* 1994;13(3):232-7.
44. Mallett CP, Hale TL, Kaminski RW, Larsen T, Orr N, **Cohen D**, Lowell GH. Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. *Infect Immun.* 1995;63(6):2382-6.
45. **Cohen D**, Ashkenazi S, Green M, Gdalevich M, Yavzori M, Orr N, Robin G, Slepon R, Lerman Y, Block C, Ashkenazi I, Taylor D, Hale L, Sadoff J, Schneerson R, Robbins J, Wiener M, Shemer J. Clinical trials of Shigella vaccines in Israel. *Advances in Experimental Medicine and Biology.* 1996;397:159-67.
46. **Cohen D**, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, Orr N, Taylor DN, Sadoff JC, Chu C, Shiloach J, Schneerson R, Robbins JB. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. *Infect Immun.* 1996;64(10):4074-7.
47. **Cohen D**, Orr N, Robin G, Slepon R, Ashkenazi S, Ashkenazi I, Shemer J. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination. *Clin Diagn Lab Immunol.* 1996;3(4):451-5.
48. Ephros M, **Cohen D**, Yavzori M, Rotman N, Novic B, Ashkenazi S. Encephalopathy associated with enteroinvasive Escherichia coli 0144:NM infection. *J Clin Microbiol.* 1996;34(10):2432-4.
49. Mendelson E, Duvdevani P, Varsano N, Lerman Y, Slepon R, Dagan R, **Cohen D**, Danon Y, Shohat T. Measles immunity and response to revaccination of a young adult population in Israel. *J Med Virol.* 1996;50(3):249-53.
50. **Cohen D**, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. *Lancet.* 1997;349(9046):155-9.
51. Haim M, **Cohen D**, Ashkenazi I. [Acute gastroenteritis caused by small round viruses]. *Harefuah.* 1997;132(6):427-31.
52. Haim M, Efrat M, Wilson M, Schantz PM, **Cohen D**, Shemer J. An outbreak of Trichinella spiralis infection in southern Lebanon. *Epidemiol Infect.* 1997;119(3):357-62.
53. Robin G, **Cohen D**, Orr N, Markus I, Slepon R, Ashkenazi S, Keisari Y. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection. *J Infect Dis.* 1997;175(5):1128-33.

54. Haim M, **Cohen D**, Ashkenazi I. [Diarrheal diseases caused to enterotoxigenic *Escherichia coli* (ETEC)]. *Harefuah*. 1998;134(6):481-6.
55. Low M, Almog R, Green MS, Ashkenazi S, Bercovier H, Katzenelson E, Ashkenazi I, Shemer J, **Cohen D**. Immune status against diphtheria among immigrants from the former USSR who arrived in Israel during 1990-1991. *Infection*. 1998;26(2):104-8.
56. Metzger E, Agmon V, Andoren N, **Cohen D**. Emergence of multidrug-resistant *Salmonella enterica* serotype Typhimurium phage-type DT104 among salmonellae causing enteritis in Israel. *Epidemiol Infect*. 1998;121(3):555-9.
57. Turner D, Porat N, **Cohen D**, Yavzori M, Fraser D, Peled N, Ohana O, Dagan R. Antibiotic resistance pattern of enterotoxigenic *Escherichia coli* isolated from infants and young adults in Israel. *Eur J Clin Microbiol Infect Dis*. 1998;17(9):666-9.
58. Yavzori M, Porath N, Ochana O, Dagan R, Orni-Wasserlauf R, **Cohen D**. Detection of enterotoxigenic *Escherichia coli* in stool specimens by polymerase chain reaction. *Diagn Microbiol Infect Dis*. 1998;31(4):503-9.
59. Almog R, Low M, **Cohen D**, Robin G, Ashkenazi S, Bercovier H, Gdalevich M, Samuels Y, Ashkenazi I, Shemer J, Eldad A, Green MS. Prevalence of anti-hepatitis A antibodies, hepatitis B viral markers, and anti-hepatitis C antibodies among immigrants from the former USSR who arrived in Israel during 1990-1991. *Infection*. 1999;27(3):212-7.
60. **Cohen D**, Zaide Y, Karasenty E, Schwarz M, LeDuc JW, Slepon R, Ksiazek TG, Shemer J, Green MS. Prevalence of antibodies to West Nile fever, sandfly fever Sicilian, and sandfly fever Naples viruses in healthy adults in Israel. *Public Health Rev*. 1999;27(1-3):217-30.
61. Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, **Cohen D**, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL. Vaccination against shigellosis with attenuated *Shigella flexneri* 2a strain SC602. *Infect Immun*. 1999;67(7):3437-43.
62. Koton S, **Cohen D**, Green MS. [Diarrheal disease among caregivers at children's day-care centers. A retrospective and seroepidemiologic study]. *Harefuah*. 1999;136(2):97-101, 76.
63. Robin G, Keisari Y, Slepon R, Ashkenazi S, **Cohen D**. Quantitative analysis of IgG class and subclass and IgA serum response to *Shigella sonnei* and *Shigella flexneri* 2a polysaccharides following vaccination with *Shigella* conjugate vaccines. *Vaccine*. 1999;17(23-24):3109-15.
64. Arav-Boger R, Ashkenazi S, Gdalevich M, **Cohen D**, Danon YL. Seroprevalence of pertussis antibodies among adolescents in Israel. *Isr Med Assoc J*. 2000;2(2):174-7.
65. Avrahami-Heller Y, **Cohen D**, Orr N, Slepon R, Ashkenazi I, Danon YL. Immunity to varicella zoster virus in young Israeli adults. *Isr Med Assoc J*. 2000;2(3):196-9.
66. **Cohen D**, Orr N, Haim M, Ashkenazi S, Robin G, Green MS, Ephros M, Sela T, Slepon R, Ashkenazi I, Taylor DN, Svennerholm AM, Eldad A, Shemer J. Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic *Escherichia coli*-cholera toxin B subunit vaccine in Israeli young adults. *Infect Immun*. 2000;68(8):4492-7.
67. Gdalevich M, **Cohen D**, Ashkenazi I, Mimouni D, Shpilberg O, Kark JD. *Helicobacter pylori* infection and subsequent peptic duodenal disease among young adults. *Int J Epidemiol*. 2000;29(3):592-5.

68. Huerta M, Grotto I, Gdalevich M, Mimouni D, Gavrieli B, Yavzori M, **Cohen D**, Shpilberg O. A waterborne outbreak of gastroenteritis in the Golan Heights due to enterotoxigenic *Escherichia coli*. *Infection*. 2000;28(5):267-71.
69. Yavzori M, Uriel N, Porat N, Dagan R, Ambar R, Shpilberg O, **Cohen D**. [Development of molecular tests for rapid detection of enteropathogens]. *Harefuah*. 2000;138(9):758-62, 805.
70. **Cohen D**, Sela T, Slepon R, Yavzori M, Ambar R, Orr N, Robin G, Shpielberg O, Eldad A, Green M. Prospective cohort studies of shigellosis during military field training. *Eur J Clin Microbiol Infect Dis*. 2001;20(2):123-6.
71. Robin G, Fraser D, Orr N, Sela T, Slepon R, Ambar R, Dagan R, Le Blancq S, Deckelbaum RJ, **Cohen D**. *Cryptosporidium* infection in Bedouin infants assessed by prospective evaluation of anticryptosporidial antibodies and stool examination. *Am J Epidemiol*. 2001;153(2):194-201.
72. **Cohen D**, Monroe SS, Haim M, Slepon R, Ashkenazi I, Estes MK, Glass RI. Norwalk virus gastroenteritis among Israeli soldiers: lack of evidence for flyborne transmission. *Infection*. 2002;30(1):3-6.
73. Dagan D, Orr N, Yavzori M, Yuhas Y, Meron D, Ashkenazi S, **Cohen D**. Retrospective analysis of the first clonal outbreak of nalidixic acid-resistant *Shigella sonnei* shigellosis in Israel. *Eur J Clin Microbiol Infect Dis*. 2002;21(12):887-9.
74. Yavzori M, **Cohen D**, Orr N. Prevalence of the genes for shigella enterotoxins 1 and 2 among clinical isolates of shigella in Israel. *Epidemiol Infect*. 2002;128(3):533-5.
75. Grotto I, Mimouni D, Huerta M, Mimouni M, **Cohen D**, Robin G, Pitlik S, Green MS. Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults. *Epidemiol Infect*. 2003;131(1):683-9.
76. Klement E, Uliel L, Engel I, Hasin T, Yavzori M, Orr N, Davidovitz N, Lahat N, Srugo I, Zangvil E, **Cohen D**. An outbreak of pertussis among young Israeli soldiers. *Epidemiol Infect*. 2003;131(3):1049-54.
77. Gdalevich M, **Cohen D**, Yosef D, Tauber C. Morbidity and mortality after hip fracture: the impact of operative delay. *Arch Orthop Trauma Surg*. 2004;124(5):334-40.
78. Grotto I, Huerta M, Balicer RD, Halperin T, **Cohen D**, Orr N, Gdalevich M. An outbreak of norovirus gastroenteritis on an Israeli military base. *Infection*. 2004;32(6):339-43.
79. Katz DE, Coster TS, Wolf MK, Trespalacios FC, **Cohen D**, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL. Two studies evaluating the safety and immunogenicity of a live, attenuated *Shigella flexneri* 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. *Infect Immun*. 2004;72(2):923-30.
80. Orr N, Forman M, Marcus H, Lustig S, Paran N, Grotto I, Klement E, Yehezkeli Y, Robin G, Reuveny S, Shafferman A, **Cohen D**. Clinical and immune responses after revaccination of Israeli adults with the Lister strain of vaccinia virus. *J Infect Dis*. 2004;190(7):1295-302.
81. Weinberger M, Andorn N, Agmon V, **Cohen D**, Shohat T, Pitlik SD. Blood invasiveness of *Salmonella enterica* as a function of age and serotype. *Epidemiol Infect*. 2004;132(6):1023-8.
82. Balicer RD, Davidovitch N, Huerta M, **Cohen D**, Grotto I. [Smallpox vaccination techniques: considerations and unresolved issues]. *Harefuah*. 2005;144(1):51-6, 69.

83. Balicer RD, Grotto I, Huerta M, Leventhal A, Zach R, Yahalom V, Davidovitch N, Huerta M, **Cohen D**, Grotto I. Beveled needle technique is not associated with low "take" rates in Israeli smallpox revaccination campaign. *Hum Vaccin*. 2005;1(6):224-7.
84. Bisharat N, **Cohen DI**, Harding RM, Falush D, Crook DW, Peto T, Maiden MC. Hybrid *Vibrio vulnificus*. *Emerg Infect Dis*. 2005;11(1):30-5.
85. Klement E, Grotto I, Srugo I, Orr N, Gilad, J, Cohen D. High prevalence and incidence of Pertussis among Young Soldiers in Israel. *Emerg Infect Dis*. 2005;11(3): 506-508.
86. Calderon-Margalit R, Sheffer R, Halperin T, Orr N, **Cohen D**, Shohat T. A large-scale gastroenteritis outbreak associated with Norovirus in nursing homes. *Epidemiol Infect*. 2005;133(1):35-40.
87. Green MS, Weinberger M, Ben-Ezer J, Bin H, Mendelson E, Gandacu D, Kaufman Z, Dichtiar R, Sobel A, **Cohen D**, Chowers MY. Long-term Death Rates, West Nile virus epidemic, Israel, 2000. *Emerg Infect Dis*. 2005;11(11):1754-7.
88. Halperin T, Yavzori M, Amitai A, Klement E, Kayouf R, Grotto I, Huerta M, Hadley LA, Monroe SS, **Cohen D**, Orr N. Molecular analysis of noroviruses involved in acute gastroenteritis outbreaks in military units in Israel, 1999-2004. *Eur J Clin Microbiol Infect Dis*. 2005;24(10):697-700.
89. Huerta M, Schwaber MJ, Davidovitch N, Balicer RD, Zelikovitch Y, **Cohen D**, Grotto I. Trends in *Shigella* outbreaks in the Israeli military over 15 years. *Eur J Clin Microbiol Infect Dis*. 2005;24(1):71-3.
90. Kafatos G, Andrews N, Nardone A, Backhouse J, Gilbert L, Broodhaers S, Van Damme P, De Cock L, Theeten H, Vranckx R, Gatcheva N, Mihneva Z, Voynova V, Hadjianastassiou C, Zarvou M, Kriz B, Nemecek V, Andrews N, Edmunds WJ, Gay N, Gelb D, Hesketh L, Kafatos G, Miller E, Morgan-Capner P, Nardone A, Pebody R, Davidkin I, Ölander RM, Valle M, Hellenbrand W, Thierfelder W, Tischer A, Anastassopoulou C, Hatzakis A, Tsakris A, Bartha K, Karacs I, Lontai I, Melles M, Carton M, Jones L, O'Flanagan D, Aboudy Y, **Cohen D**. Model selection methodology for inter-laboratory standardisation of antibody titres. *Vaccine*. 2005;23(42):5022-7.
91. Klement E, Kagan N, Hagain L, Kayouf R, Boxman J, **Cohen D**, Orr N. Correlation of IgA, IgM and IgG antibody-detecting assays based on filamentous haemagglutinin, pertussis toxin and *Bordetella pertussis* sonicate in a strictly adult population. *Epidemiol Infect*. 2005;133(1):149-58.
92. Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, Sela T, Kayouf R, Klein Z, Ambar R, **Cohen D**, Wolf MK, Venkatesan MM, Hale TL. Community-based safety, immunogenicity, and transmissibility study of the *Shigella sonnei* WRSS1 vaccine in Israeli volunteers. *Infect Immun*. 2005;73(12):8027-32.
93. Athamna A, **Cohen D**, Athamna M, Ofek I, Stavri H. Rapid identification of *Mycobacterium* species by lectin agglutination. *J Microbiol Methods*. 2006;65(2):209-15.
94. **Cohen D**, Muhsen K, Aboudy Y, Harari H, Mendelson E, Green MS. Use of rubella seroepidemiological data for assessment of previous vaccination policy and for decision making in response to epidemics in Israel. *Vaccine*. 2006;24(27-28):5604-8.

95. **Cohen DI**, Davidovici BB, Smetana Z, Balicer RD, Klement E, Mendelson E, Green MS. Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines. *Infection*. 2006;34(4):208-13.
96. Davidovici BB, Green M, Marouni MJ, Bassal R, Pimenta JM, **Cohen D**. Seroprevalence of herpes simplex virus 1 and 2 and correlates of infection in Israel. *J Infect*. 2006;52(5):367-73.
97. Davidovici BB, Grotto I, Balicer RD, Robinson NJ, **Cohen D**. Decline in the prevalence of antibodies to herpes simplex virus types 1 and 2 among Israeli young adults between 1984 and 2002. *Sex Transm Dis*. 2006;33(11):641-5.
98. de Ory F, Echevarria JM, Kafatos G, Anastassopoulou C, Andrews N, Backhouse J, Berbers G, Bruckova B, **Cohen DI**, de Melker H, Davidkin I, Gabutti G, Hesketh LM, Johansen K, Jokinen S, Jones L, Linde A, Miller E, Mossong J, Nardone A, Rota MC, Sauerbrei A, Schneider F, Smetana Z, Tischer A, Tsakris A, Vranckx R. European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus. *J Clin Virol*. 2006;36(2):111-8.
99. Halperin T, Orr N, Cohen R, Hasin T, Davidovitch N, Klement E, Kayouf R, Baneth G, **Cohen D**, Yavzori M. Detection of relapsing fever in human blood samples from Israel using PCR targeting the glycerophosphodiester phosphodiesterase (GlpQ) gene. *Acta Trop*. 2006;98(2):189-95.
100. Hasin T, Davidovitch N, Cohen R, Dagan T, Romem A, Orr N, Klement E, Lubezky N, Kayouf R, Sela T, Keller N, Derazne E, Halperin T, Yavzori M, Grotto I, **Cohen D**. Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. *N Engl J Med*. 2006;355(2):148-55.
101. Muhsen K, Athamna A, Athamna M, Spungin-Bialik A, **Cohen D**. Prevalence and risk factors of *Helicobacter pylori* infection among healthy 3- to 5-year-old Israeli Arab children. *Epidemiol Infect*. 2006;134(5):990-6.
102. Muhsen K, Athamna A, Athamna M, Spungin-Bialik A, **Cohen D**. Evaluation of a urine-based enzyme-linked immunosorbent assay test for the detection of *Helicobacter pylori* infection among 3- to 5-year-old Israeli Arab healthy children. *J Pediatr Gastroenterol Nutr*. 2006;43(3):398-401.
103. Orr N, Klement E, Gillis D, Sela T, Kayouf R, Derazne E, Grotto I, Balicer R, Huerta M, Aviram L, Ambar R, Epstein Y, Heled Y, **Cohen D**. Long-term immunity in young adults after a single dose of inactivated Hepatitis A vaccines. *Vaccine*. 2006;24(20):4328-32.
104. Valinsky L, Simhoni S, Bassal R, Agmon V, Yishai R, Green MS, **Cohen D**. Prevalence and correlates of diphtheria toxoid antibodies in children and adults in Israel. *Clin Microbiol Infect*. 2006;12(10):968-73.
105. Weinberger M, Solnik-Isaac H, Shachar D, Reisfeld A, Valinsky L, Andorn N, Agmon V, Yishai R, Bassal R, Fraser A, Yaron S, **Cohen D**. Salmonella enterica serotype Virchow: epidemiology, resistance patterns and molecular characterisation of an invasive Salmonella serotype in Israel. *Clin Microbiol Infect*. 2006;12(10):999-1005.
106. Bisharat N, Amaro C, Fouz B, Llorens A, **Cohen DI**. Serological and molecular characteristics of *Vibrio vulnificus* biotype 3: evidence for high clonality. *Microbiology*. 2007;153(Pt 3):847-56.

107. Bisharat N, **Cohen DI**, Maiden MC, Crook DW, Peto T, Harding RM. The evolution of genetic structure in the marine pathogen, *Vibrio vulnificus*. *Infect Genet Evol.* 2007;7(6):685-93.
108. Davidovici BB, Balicer RD, Klement E, Green MS, Mendelson E, Smetana Z, **Cohen D**. Comparison of the dynamics and correlates of transmission of Herpes Simplex Virus-1 (HSV-1) and Varicella-Zoster Virus (VZV) in a sample of the Israeli population. *Eur J Epidemiol.* 2007;22(9):641-6.
109. Hasin T, Dagan R, Boutboul G, Derazne E, Atias O, **Cohen D**. Socioeconomic correlates of antibody levels to enteric pathogens among Israeli adolescents. *Epidemiol Infect.* 2007;135(1):118-25.
110. Muhsen K, Athamna A, **Cohen D**. [Incidence and risk factors of diarrheal diseases among 3-5 year old Israeli Arab children attending kindergartens]. *Harefuah.* 2007;146(5):341-4, 407.
111. Nardone A, de Ory F, Carton M, **Cohen D**, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, Tischer A, Andrews N, Berbers G, Gabutti G, Gay N, Jones L, Jokinen S, Kafatos G, de Aragón MV, Schneider F, Smetana Z, Vargova B, Vranckx R, Miller E. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. *Vaccine.* 2007;25(45):7866-72.
112. Paz S, Bisharat N, Paz E, Kidar O, **Cohen D**. Climate change and the emergence of *Vibrio vulnificus* disease in Israel. *Environ Res.* 2007;103(3):390-6.
113. Rosenberg M, Knaan T, **Cohen D**. Association among bad breath, body mass index, and alcohol intake. *J Dent Res.* 2007;86(10):997-1000.
114. Sjöling Å, Wiklund G, Savarino SJ, **Cohen DI**, Svennerholm AM. Comparative analyses of phenotypic and genotypic methods for detection of enterotoxigenic *Escherichia coli* toxins and colonization factors. *Journal of Clinical Microbiology.* 2007;45(10):3295-301.
115. Vasilev V, Japheth R, Yishai R, Andorn N, Valinsky L, Navon-Venezia S, Chmelnitsky I, Carmeli Y, **Cohen D**. Extended-spectrum beta-lactamase-producing *Shigella* strains in Israel, 2000-2004. *Eur J Clin Microbiol Infect Dis.* 2007;26(3):189-94.
116. Andrews N, Tischer A, Siedler A, Pebody RG, Barbara C, Cotter S, Duks A, Gacheva N, Bohumir K, Johansen K, Mossong J, Ory F, Prosenc K, Slacikova M, Theeten H, Zarvou M, Pistol A, Bartha K, **Cohen D**, Backhouse J, Griskevicius A. Towards elimination: measles susceptibility in Australia and 17 European countries. *Bull World Health Organ.* 2008;86(3):197-204.
117. Muhsen K, Aboudy Y, Mendelson E, Green MS, **Cohen D**. Prevalence of mumps antibodies in the Israeli population in relation to mumps vaccination policy and incidence of disease. *Epidemiol Infect.* 2008;136(5):688-93.
118. Muhsen K, **Cohen D**. *Helicobacter pylori* infection and iron stores: a systematic review and meta-analysis. *Helicobacter.* 2008;13(5):323-40.
119. Nardone A, Tischer A, Andrews N, Backhouse J, Theeten H, Gacheva N, Zarvou M, Kriz B, Pebody RG, Bartha K, O'Flanagan D, **Cohen D**, Duks A, Griskevicius A, Mossong J, Barbara C, Pistol A, Slaciková M, Prosenc K, Johansen K, Miller E. Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets. *Bull World Health Organ.* 2008;86(2):118-25.

120. Sharkia R, Zaid M, Athamna A, **Cohen D**, Azem A, Zalan A. The changing pattern of consanguinity in a selected region of the Israeli Arab community. *Am J Hum Biol.* 2008;20(1):72-7.
121. Tobias J, Andersson K, Bialik A, **Cohen D**. Preexisting antibodies to homologous colonization factors and heat-labile toxin in serum, and the risk to develop enterotoxigenic *Escherichia coli*-associated diarrhea. *Diagn Microbiol Infect Dis.* 2008;60(2):229-31.
122. Anastassopoulou CG, Kafatos G, Nardone A, Andrews N, Pebody RG, Mossong J, Davidkin I, Gelb D, Ory F Thierfelder W, Nemecek V, Bruzzone B, Butur D, Barbara C, Sobotova Z, Jones L, Griskevicius A, Hesketh L, M, **Cohen D**, Vranckx R, Tsakris A, Miller E, Hatzakis A. The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries. *Epidemiol Infect.* 2009;137(4):485-94.
123. Muhsen K, Barak M, Shifnaidel L, Nir A, Bassal R, **Cohen D**. *Helicobacter pylori* infection is associated with low serum ferritin levels in Israeli Arab children: a seroepidemiologic study. *J Pediatr Gastroenterol Nutr.* 2009;49(2):262-4.
124. Muhsen K, Shulman L, Rubinstein U, Kasem E, Kremer A, Goren S, Zilberstein I, Chodick G, Ephros M, **Cohen D**. Incidence, characteristics, and economic burden of rotavirus gastroenteritis associated with hospitalization of Israeli children <5 years of age, 2007-2008. *J Infect Dis.* 2009;200 Suppl 1:S254-63.
125. Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Belot F, **Cohen D**, Sansonetti PJ, Mulard LA. A synthetic carbohydrate-protein conjugate vaccine candidate against *Shigella flexneri* 2a infection. *J Immunol.* 2009;182(4):2241-7.
126. Vasilev V, Japheth R, Andorn N, Yshai R, Agmon V, Gazit E, Kashi Y, **Cohen D**. A survey of laboratory-confirmed isolates of invasive listeriosis in Israel, 1997-2007. *Epidemiol Infect.* 2009;137(4):577-80.
127. **Cohen D**, Gargouri N, Ramlawi A, Abdeen Z, Belbesi A, Al Hijawi B, Haddadin A, Sheikh Ali S, Al Shuaibi N, Bassal R, Yishai R, Green MS, Leventhal A. A Middle East subregional laboratory-based surveillance network on foodborne diseases established by Jordan, Israel, and the Palestinian Authority. *Epidemiology and infection.* 2010;138(10):1443-8.
128. **Cohen D**, Tobias J, Spungin-Bialik A, Sela T, Kayouf R, Volovik Y, Yavzori M, Ephros M. Phenotypic characteristics of enterotoxigenic *Escherichia coli* associated with acute diarrhea among Israeli young adults. *Foodborne pathogens and disease.* 2010;7(10):1159-64.
129. Muhsen K, Athamna A, Bialik A, Alpert G, **Cohen D**. Presence of *Helicobacter pylori* in a sibling is associated with a long-term increased risk of *H. pylori* infection in Israeli Arab children. *Helicobacter.* 2010;15(2):108-13.
130. Muhsen K, Athamna A, Bialik A, Alpert G, **Cohen D**. Presence of *Helicobacter pylori* in a Sibling is Associated with a Long-Term Increased Risk of *H-pylori* Infection in Israeli Arab Children. *Helicobacter.* 2010;15(2):108-13.
131. Muhsen K, Barak M, Henig C, Alpert G, Ornoy A, **Cohen D**. Is the Association Between *Helicobacter pylori* Infection and Anemia Age Dependent? *Helicobacter.* 2010;15(5):467-72.
132. Muhsen K, Chodick G, Goren S, Shalev V, **Cohen D**. The uptake of rotavirus vaccine and its effectiveness in preventing acute gastroenteritis in the community. *Vaccine.* 2010;29(1):91-4.

133. Muhsen K, Na'annah W, Lesser Y, Volovik I, **Cohen D**, Shohat T. Determinates of underutilization of amniocentesis among Israeli Arab women. *Prenatal diagnosis*. 2010;30(2):138-43.
134. Muhsen K, Shulman L, Kasem E, Rubinstein U, Shachter J, Kremer A, Goren S, Zilberstein I, Chodick G, Ephros M, **Cohen D**. Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel A case-control study. *Human vaccines*. 2010;6(6):450-4.
135. Rendi-Wagner P, Tobias J, Moerman L, Goren S, Bassal R, Green M, **Cohen D**. The seroepidemiology of Bordetella pertussis in Israel--Estimate of incidence of infection. *Vaccine*. 2010;28(19):3285-90.
136. Rendi-Wagner P, Tobias J, Moerman L, Goren S, Bassal R, Green M, **Cohen D**. The seroepidemiology of Bordetella pertussis in Israel-Estimate of incidence of infection. *Vaccine*. 2010;28(19):3285-90.
137. Wisner I, Orr N, Kaufman B, Segev S, Smetana Z, Bialik A, Epstein N, Mendelson E, Catane R, **Cohen D**. Immunosuppressive Treatments Reduce Long-Term Immunity to Smallpox among Patients with Breast Cancer. *J Infect Dis*. 2010;201(10):1527-34.
138. Bisharat N, Bialik A, Paz E, Amaro C, **Cohen DI**. Serum antibodies to Vibrio vulnificus biotype 3 lipopolysaccharide and susceptibility to disease caused by the homologous V. vulnificus biotype. *Epidemiology and infection*. 2011;139(3):472-81.
139. Muhsen K, Masarwa S, Guttman E, **Cohen D**. [What are the determinants of early breastfeeding weaning and prolonged breastfeeding in Arab infants?]. *Harefuah*. 2011;150(4):333-7, 420.
140. Muhsen K, Nir A, Spungin-Bialik A, Bassal R, Goren S, **Cohen D**. Interaction among ethnicity, socioeconomic status, and Helicobacter pylori seroprevalence in Israeli children and adolescents. *Journal of pediatric gastroenterology and nutrition*. 2011;53(5):524-7.
141. Muhsen K, Ornoy A, Akawi A, Alpert G, **Cohen D**. An association between Helicobacter pylori infection and cognitive function in children at early school age: a community-based study. *BMC pediatrics*. 2011;11:43.
142. Muhsen K, Shohat T, Aboudy Y, Mendelson E, Algor N, Anis E, **Cohen D**. Sero-prevalence of mumps antibodies in subpopulations subsequently affected by a large scale mumps epidemic in Israel. *Vaccine*. 2011;29(22):3878-82.
143. Wisner I, Orr N, Smetana Z, Spungin-Bialik A, Mendelson E, **Cohen D**. Alternative immunological markers to document successful multiple smallpox revaccinations. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011;52(7):856-61.
144. Ziv T, Heymann AD, Azuri J, Leshno M, **Cohen D**. Assessment of the underestimation of childhood diarrhoeal disease burden in Israel. *Epidemiology and infection*. 2011;139(9):1379-87.
145. Bassal R, Reisfeld A, Andorn N, Yishai R, Nissan I, Agmon V, Peled N, Block C, Keller N, Kenes Y, Taran D, Schemberg B, Ken-Dror S, Rouach T, Citron B, Berman E, Green MS, Shohat T, **Cohen D**. Recent trends in the epidemiology of non-typhoidal Salmonella in Israel, 1999-2009. *Epidemiology and infection*. 2012;140(8):1446-53.

146. **Cohen D**, Muhsen K. Association between *Helicobacter pylori* colonization and glycosylated hemoglobin levels: is this another reason to eradicate *H. pylori* in adulthood? *J Infect Dis.* 2012;205(8):1183-5.
147. **Cohen D**, Shoham O, Orr N, Muhsen K. An inverse and independent association between *Helicobacter pylori* infection and the incidence of shigellosis and other diarrheal diseases. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2012;54(4):e35-42.
148. Kotloff KL, Blackwelder WC, Nasrin D, Nataro JP, Farag TH, van Eijk A, Adegbola RA, Alonso PL, Breiman RF, Faruque AS, Saha D, Sow SO, Sur D, Zaidi AK, Biswas K, Panchalingam S, Clemens JD, **Cohen D**, Glass RI, Mintz ED, Sommerfelt H, Levine MM. The Global Enteric Multicenter Study (GEMS) of diarrheal disease in infants and young children in developing countries: epidemiologic and clinical methods of the case/control study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2012;55 Suppl 4:S232-45.
149. Levine H, Balicer RD, Zarka S, Sela T, Rozhavski V, **Cohen D**, Kayouf R, Ambar R, Porat N, Dagan R. Dynamics of Pneumococcal Acquisition and Carriage in Young Adults during Training in Confined Settings in Israel. *PloS one.* 2012;7(10):7.
150. Levine H, Zarka S, Dagan R, Sela T, Rozhavski V, **Cohen DI**, Balicer RD. Transmission of *Streptococcus pneumoniae* in adults may occur through saliva. *Epidemiology and infection.* 2012;140(3):561-5.
151. Muhsen K, Abed El-Hai R, Amit-Aharon A, Nehama H, Gondia M, Davidovitch N, Goren S, **Cohen D**. Risk factors of underutilization of childhood immunizations in ultraorthodox Jewish communities in Israel despite high access to health care services. *Vaccine.* 2012;30(12):2109-15.
152. Muhsen K, **Cohen D**, Spungin-Bialik A, Shohat T. Seroprevalence, correlates and trends of *Helicobacter pylori* infection in the Israeli population. *Epidemiology and infection.* 2012;140(7):1207-14.
153. Muhsen K, Jurban M, Goren S, **Cohen D**. Incidence, age of acquisition and risk factors of *Helicobacter pylori* infection among Israeli Arab infants. *Journal of tropical pediatrics.* 2012;58(3):208-13.
154. Shulman LM, Hindiyeh M, Muhsen K, **Cohen D**, Mendelson E, Sofer D. Evaluation of four different systems for extraction of RNA from stool suspensions using MS-2 coliphage as an exogenous control for RT-PCR inhibition. *PloS one.* 2012;7(7):e39455.
155. Ziv-Baran T, **Cohen D**, Rahav G, Leshno M. [How to build a predictive model and how to predict the individual outcome?]. *Harefuah.* 2012;151(11):647-9.
156. di Giovine P, Kafatos G, Nardone A, Andrews N, Olander RM, Alfaroni G, Broughton K, **Cohen D**, Kriz B, Mikova I, O'Flanagan D, Schneider F, Selga I, Valinsky L, Velicko I, Karacs I, Pebody R, von Hunolstein C. Comparative seroepidemiology of diphtheria in six European countries and Israel. *Epidemiology and infection.* 2013;141(1):132-42.
157. Eriksen J, Davidkin I, Kafatos G, Andrews N, Barbara C, **Cohen D**, Duks A, Giskevicius A, Johansen K, Bartha K, Kriz B, Mitis G, Mossong J, Nardone A, O'Flanagan D, F DEO, Pistol A, Theeten H, Prosenc K, Slacikova M, Pebody R. Seroepidemiology of mumps in Europe

- (1996-2008): why do outbreaks occur in highly vaccinated populations? *Epidemiology and infection*. 2013;141(3):651-66.
158. Farag TH, Faruque AS, Wu Y, Das SK, Hossain A, Ahmed S, Ahmed D, Nasrin D, Kotloff KL, Panchilangam S, Nataro JP, **Cohen D**, Blackwelder WC, Levine MM. Housefly population density correlates with shigellosis among children in Mirzapur, Bangladesh: a time series analysis. *PLoS neglected tropical diseases*. 2013;7(6):e2280.
 159. Feldman N, Adler A, Molshatzki N, Navon-Venezia S, Khabra E, **Cohen D**, Carmeli Y. Gastrointestinal colonization by KPC-producing *Klebsiella pneumoniae* following hospital discharge: duration of carriage and risk factors for persistent carriage. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2013;19(4):E190-6.
 160. Leventhal A, Ramlawi A, Belbiesi A, Sheikh S, Haddadin A, Hussein S, Abdeen Z, **Cohen D**. Enhanced surveillance for detection and management of infectious diseases: regional collaboration in the middle East. *Emerging health threats journal*. 2013;6.
 161. Muhsen K, **Cohen D**. *Helicobacter pylori* infection and anemia. *The American journal of tropical medicine and hygiene*. 2013;89(2):398.
 162. Muhsen K, **Cohen D**, Levine MM. Can *Giardia lamblia* infection lower the risk of acute diarrhea among preschool children? *Journal of tropical pediatrics*. 2013;60(2):99-103.
 163. Muhsen K, Kassem E, Rubinstein U, Schachter Y, Kremer A, Goren S, Zilberstein I, Ephros M, **Cohen D**, Shulman LM. Incidence and characteristics of sporadic norovirus gastroenteritis associated with hospitalization of children less than 5 years of age in Israel. *The Pediatric infectious disease journal*. 2013;32(6):688-90.
 164. Weil M, Shohat T, Bromberg M, Bassal R, Dichtiar R, Mandelboim M, Sofer D, **Cohen D**, Mendelson E. The dynamics of infection and the persistence of immunity to A(H1N1)pdm09 virus in Israel. *Influenza and other respiratory viruses*. 2013;7(5):838-46.
 165. Aharonson-Raz K, Lichter-Peled A, Tal S, Gelman B, **Cohen D**, Klement E, Steinman A. Spatial and temporal distribution of West Nile virus in horses in Israel (1997-2013)--from endemic to epidemics. *PloS one*. 2014;9(11):e113149.
 166. Bassal R, Reisfeld A, Nissan I, Agmon V, Taran D, Schemberg B, **Cohen D**, Shohat T. Risk factors for sporadic infection with *Salmonella Infantis*: a matched case-control study. *Epidemiology and infection*. 2014;142(4):820-5.
 167. Bassal R, Schejter E, Bachar R, Shapira H, Sandbank J, Rosin LS, Schvimer M, **Cohen D**, Keinan-Boker L. Cervical Pap screening among Israeli women, 2005-2010. *Archives of gynecology and obstetrics*. 2014;289(3):615-22.
 168. **Cohen D**, Bassal R, Goren S, Rouach T, Taran D, Schemberg B, Peled N, Keness Y, Kendror S, Vasilev V, Nissan I, Agmon V, Shohat T. Recent trends in the epidemiology of shigellosis in Israel. *Epidemiology and infection*. 2014;142(12):2583-94.
 169. Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, Marohn ME, Antonio M, Hossain A, Mandomando I, Ochieng JB, Oundo JO, Qureshi S, Ramamurthy T, Tamboura B, Adegbola RA, Hossain MJ, Saha D, Sen S, Faruque AS, Alonso PL, Breiman RF, Zaidi AK, Sur D, Sow SO, Berkeley LY, O'Reilly CE, Mintz ED, Biswas K, **Cohen D**, Farag TH, Nasrin D, Wu Y, Blackwelder WC, Kotloff KL, Nataro JP, Levine MM. *Shigella* isolates from the

- global enteric multicenter study inform vaccine development. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2014;59(7):933-41.
170. Mandelboim M, Bromberg M, Sherbany H, Zucker I, Yaary K, Bassal R, Dichtiar R, **Cohen D**, Shohat T, Mendelson E, Green MS. Significant cross reactive antibodies to influenza virus in adults and children during a period of marked antigenic drift. *BMC infectious diseases*. 2014;14:346.
 171. Markovich MP, Shohat T, Riklis I, Avni R, Yujelevski-Rozenblit D, Bassal R, **Cohen D**, Rorman E. Seroepidemiology of *Toxoplasma gondii* infection in the Israeli population. *Epidemiology and infection*. 2014;142(1):149-55.
 172. Muhsen K, Kassem E, Efraim S, Goren S, **Cohen D**, Ephros M. Incidence and risk factors for intussusception among children in northern Israel from 1992 to 2009: a retrospective study. *BMC pediatrics*. 2014;14:218.
 173. Bassal R, Rosin LS, Schvimer M, Schejter E, Ozeryansky B, Kulik S, Bachar R, Shapira H, Sandbank J, **Cohen D**, Keinan-Boker L. Prevalence and Correlates of Human Papillomavirus Genotypes Among Patients With Cervical Cancer and Cervical Intraepithelial Neoplasia 3 in Israel. *Journal of lower genital tract disease*. 2015;19(2):161-4.
 174. Bassal R, Schejter E, Bachar R, Shapira H, Kaufman Z, **Cohen D**, Keinan-Boker L. Recent trends of cervical cancer and Cervical Intraepithelial Neoplasia 3 (CIN3) in Israel. *Archives of gynecology and obstetrics*. 2015;292(2):405-13.
 175. Behar A, Fookes MC, Goren S, Thomson NR, **Cohen D**. Whole genome analysis to detect potential vaccine-induced changes on *Shigella sonnei* genome. *Vaccine*. 2015;33(26):2978-83.
 176. Mor O, Bassal R, Michaeli M, Wax M, Ram D, Cohen-Ezra O, **Cohen D**, Mendelson E, Ben-Ari Z, Shohat T. Prevalence of hepatitis E virus antibodies, Israel, 2009-2010. *Emerging infectious diseases*. 2015;21(4):692-4.
 177. Muhsen K, Chodick G, Goren S, Anis E, Ziv-Baran T, Shalev V, **Cohen D**. Change in incidence of clinic visits for all-cause and rotavirus gastroenteritis in young children following the introduction of universal rotavirus vaccination in Israel. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. 2015;20(42).
 178. Muhsen K, Goren S, **Cohen D**. *Helicobacter pylori* Infection in Early Childhood and Growth at School Age. *Helicobacter*. 2015;20(6):410-7.
 179. Muhsen K, Rubenstein U, Kassem E, Goren S, Schachter Y, Kremer A, Shulman LM, Ephros M, **Cohen D**. A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in Israel. *Human vaccines & immunotherapeutics*. 2015;11(10):2475-82.
 180. Tobias J, Kassem E, Rubinstein U, Bialik A, Vutukuru SR, Navaro A, Rokney A, Valinsky L, Ephros M, **Cohen D**, Muhsen K. Involvement of main diarrheagenic *Escherichia coli*, with emphasis on enteroaggregative *E. coli*, in severe non-epidemic pediatric diarrhea in a high-income country. *BMC infectious diseases*. 2015;15:79.
 181. Armon R, Halperin T, Frenkel M, **Cohen D**, Segal E. Survey of Fungal Infections in Keratinous Tissues Among Soldiers and Susceptibility to Antifungals. *Mycoses*. 2016;59:14.

182. Baker KS, Dallman TJ, Behar A, Weill FX, Gouali M, Sobel J, Fookes M, Valinsky L, Gal-Mor O, Connor TR, Nissan I, Bertrand S, Parkhill J, Jenkins C, **Cohen D**, Thomson NR. Travel- and Community-Based Transmission of Multidrug-Resistant *Shigella sonnei* Lineage among International Orthodox Jewish Communities. *Emerging infectious diseases*. 2016;22(9):1545-53.
183. Bassal R, Lerner L, Valinsky L, Agmon V, Peled N, Block C, Keller N, Keness Y, Taran D, Shainberg B, Ken-Dror S, Treygerman O, Rouach T, Lowenthal S, Shohat T, **Cohen D**. Trends in the Epidemiology of Campylobacteriosis in Israel (1999-2012). *Foodborne pathogens and disease*. 2016;13(8):448-55.
184. Bassal R, Ovadia A, Bromberg M, Stein M, Shainberg B, Loewenthal S, Somekh E, **Cohen D**, Shohat T. Risk Factors for Sporadic Infection With *Campylobacter* Spp. Among Children in Israel: A Case-control Study. *The Pediatric infectious disease journal*. 2016;35(3):249-52.
185. Bassal R, Schejter E, Bachar R, Perri T, Korach J, Jakobson-Setton A, Ben-David LH, **Cohen D**, Keinan-Boker L. Risk Factors for Cervical Cancer and CIN3 in Jewish Women in Israel - Two Case Control Studies. *Asian Pacific journal of cancer prevention : APJCP*. 2016;17(4):2067-73.
186. Glatman-Freedman A, Kaufman Z, Kopel E, Bassal R, Taran D, Valinsky L, Agmon V, Shpriz M, **Cohen D**, Anis E, Shohat T. Near real-time space-time cluster analysis for detection of enteric disease outbreaks in a community setting. *The Journal of infection*. 2016;73(2):99-106.
187. Miller-Roll T, Na'amnih W, **Cohen D**, Carmeli Y, Adler A. Molecular types and antimicrobial susceptibility patterns of *Clostridium difficile* isolates in different epidemiological settings in a tertiary care center in Israel. *Diagnostic microbiology and infectious disease*. 2016;86(4):450-4.
188. Mor O, Ofir I, Pavel R, Bassal R, Kra-Oz Z, **Cohen D**, Shohat T, Mendelson E. Parvovirus B19V infection in Israel: prevalence and occurrence of acute infection between 2008 and 2013. *Epidemiology and infection*. 2016;144(1):207-14.
189. Muhsen K, Kassem E, Rubenstein U, Goren S, Ephros M, **Cohen D**, Shulman LM. Incidence of rotavirus gastroenteritis hospitalizations and genotypes, before and five years after introducing universal immunization in Israel. *Vaccine*. 2016;34(48):5916-22.
190. Bassal R, Markovich MP, Weil M, Shinar E, Carmeli Y, Dan M, Sofer D, Mendelson E, **Cohen D**, Shohat T. Prevalence of anti-hepatitis B surface antibodies among children and adolescents vaccinated in infancy and effect of booster dose administered within a pilot study. *Epidemiology and infection*. 2017;145(14):2890-5.
191. Bassal R, Shohat T, Kaufman Z, Mannasse B, Shinar E, Amichay D, Barak M, Ben-Dor A, Bar Haim A, **Cohen D**, Mendelson E, Lustig Y. The seroprevalence of West Nile Virus in Israel: A nationwide cross sectional study. *PloS one*. 2017;12(6):e0179774.
192. Bassal R, Weil M, **Cohen D**, Sofer D, Mendelson E, Shohat T. Seroprevalence of Hepatitis A Twelve Years After the Implementation of Toddlers' Vaccination: A Population-Based Study in Israel. *The Pediatric infectious disease journal*. 2017;36(10):e248-e51.
193. Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Scire AS, Maugard A, Marchetti E, Zancan S, Huo Z, Rondini S, Marhaba R, Finco O, Martin LB, Auerbach J, **Cohen D**, Saul A, Gerke C, Podda A. Safety Profile and Immunologic Responses of a Novel Vaccine Against

Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. *EBioMedicine*. 2017;22:164-72.

194. Lustig Y, Kaufman Z, Mendelson E, Orshan L, Anis E, Glazer Y, **Cohen D**, Shohat T, Bassal R. Spatial distribution of West Nile virus in humans and mosquitoes in Israel, 2000-2014. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2017;64:20-6.
195. Na'amnih W, Adler A, Miller-Roll T, **Cohen D**, Carmeli Y. Incidence and Risk Factors for Community and Hospital Acquisition of Clostridium difficile Infection in the Tel Aviv Sourasky Medical Center. *Infection control and hospital epidemiology*. 2017;38(8):912-20.
196. Behar A, Baker KS, Bassal R, Ezernitchi A, Valinsky L, Thomson NR, **Cohen D**. Microevolution and Patterns of Transmission of Shigella sonnei within Cyclic Outbreaks Shigellosis, Israel. *Emerging infectious diseases*. 2018;24(7):1335-9.
197. Ciancarella V, Lembo-Fazio L, Paciello I, Bruno AK, Jaillon S, Berardi S, Barbagallo M, Meron-Sudai S, **Cohen D**, Molinaro A, Rossi G, Garlanda C, Bernardini ML. Role of a fluid-phase PRR in fighting an intracellular pathogen: PTX3 in Shigella infection. *PLoS pathogens*. 2018;14(12):e1007469.
198. Cohen NA, Miller T, Na'aminh W, Hod K, Adler A, **Cohen D**, Guzner-Gur H, Santo E, Halpern Z, Carmeli Y, Maharshak N. Clostridium difficile fecal toxin level is associated with disease severity and prognosis. *United European gastroenterology journal*. 2018;6(5):773-80.
199. Muhsen K, Anis E, Rubinstein U, Kassem E, Goren S, Shulman LM, Ephros M, **Cohen D**. Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2018;24(1):53-9.
200. Muhsen K, Sinnreich R, Beer-Davidson G, Nassar H, **Cohen D**, Kark JD. Sero-prevalence of Helicobacter pylori CagA immunoglobulin G antibody, serum pepsinogens and haemoglobin levels in adults. *Scientific reports*. 2018;8(1):17616.
201. Na'amnih W, Adler A, Miller-Roll T, **Cohen D**, Carmeli Y. Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 2018;37(7):1281-8.
202. Rouach V, Goldshtein I, Wolf I, Catane R, Chodick G, Iton A, Stern N, **Cohen D**. Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer. *Journal of bone oncology*. 2018;12:91-5.
203. Sharabi S, Bassal R, Friedman N, Drori Y, Alter H, Glatman-Freedman A, Hindiyeh M, **Cohen D**, Mendelson E, Shohat T, Mandelboim M. Forty five percent of the Israeli population were infected with the influenza B Victoria virus during the winter season 2015-16. *Oncotarget*. 2018;9(5):6623-9.
204. Bassal R, Wax M, Shirazi R, Shohat T, **Cohen D**, David D, Abu-Mouch S, Abu-Ghanem Y, Mendelson E, Ben-Ari Z, Mor O. Seroprevalence of hepatitis E virus in dromedary camels, Bedouins, Muslim Arabs and Jews in Israel, 2009-2017. *Epidemiology and infection*. 2019;147:5.

205. Bercovich S, Anis E, Kassem E, Rubinstein U, Ephros M, **Cohen D**, Muhsen K. Validation of parental reports of rotavirus vaccination of their children compared to the national immunization registry. *Vaccine*. 2019;37(21):2791-6.
206. **Cohen D**, Korin H, Bassal R, Markovich MP, Sivan Y, Goren S, Muhsen K. Burden and risk factors of *Shigella sonnei* shigellosis among children aged 0-59 months in hyperendemic communities in Israel. *Int J Infect Dis*. 2019;82:117-23.
207. **Cohen D**, Meron-Sudai S, Bialik A, Asato V, Goren S, Ariel-Cohen O, Reizis A, Hochberg A, Ashkenazi S. Serum IgG antibodies to *Shigella* lipopolysaccharide antigens - a correlate of protection against shigellosis. *Human vaccines & immunotherapeutics*. 2019;15(6):1401-8.
208. **Cohen D**, Muhsen K. Vaccines for enteric diseases. *Human vaccines & immunotherapeutics*. 2019;15(6):1205-14.
209. Falup-Pecurariu O, Lixandru RI, Cojocaru E, Csutak K, Monescu V, Muhsen K, Falup-Pecurariu C, **Cohen D**. Shiga toxin producing *Escherichia coli*-associated diarrhea and hemolytic uremic syndrome in young children in Romania. *Gut Pathogens*. 2019;11(1):7.
210. Kaminski RW, Pasetti MF, Aguilar AO, Clarkson KA, Rijpkema S, Bourgeois AL, **Cohen D**, Feavers I, MacLennan CA. Consensus Report on *Shigella* Controlled Human Infection Model: Immunological Assays. *Clin Infect Dis*. 2019;69:S596-S601.
211. Katz D, Ben-Chetrit E, Sherer SS, **Cohen D**, Muhsen K. Correlates of non-typhoidal *Salmonella* bacteraemia: A case-control study. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2019;81:170-5.
212. Koren R, Bassal R, Shohat T, **Cohen D**, Mor O, Mendelson E, Lustig Y. Presence of Antibodies against Sindbis Virus in the Israeli Population: A Nationwide Cross-Sectional Study. *Viruses-Basel*. 2019;11(6):10.
213. Mani S, Toapanta FR, McArthur MA, Qadri F, Svennerholm AM, Devriendt B, Phalipon A, **Cohen D**, Sztein MB. Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and *Shigella* infections, and their potential to serve as correlates of protection in vaccine development. *Vaccine*. 2019;37(34):4787-93.
214. Muhsen K, Kassem E, Rubenstein U, Goren S, Ephros M, Shulman LM, **Cohen D**. No evidence of an increase in the incidence of norovirus gastroenteritis hospitalizations in young children after the introduction of universal rotavirus immunization in Israel. *Human vaccines & immunotherapeutics*. 2019;15(6):1284-93.
215. Muhsen K, Sinnreich R, Merom D, Beer-Davidson G, Nassar H, **Cohen D**, Kark JD. Prevalence and determinants of serological evidence of atrophic gastritis among Arab and Jewish residents of Jerusalem: a cross-sectional study. *BMJ open*. 2019;9(1):e024689.
216. Muhsen K, Sinnreich R, Merom D, Nassar H, **Cohen D**, Kark JD. *Helicobacter pylori* infection, serum pepsinogens as markers of atrophic gastritis, and leukocyte telomere length: a population-based study. *Hum Genomics*. 2019;13:11.
217. Raz Y, Keinan-Boker L, Goren S, Soen-Grisaru G, **Cohen D**, Grisaru D. The effect of age at immigration on cervical cancer incidence: a population-based cohort study of 1 486 438 Israeli women. *Int J Gynecol Cancer*. 2019;29(3):492-6.

218. Rouach V, Goldshtein I, Buch A, Catane R, Chodick G, Stern N, Shalev V, **Cohen D**. The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women. *Journal of bone oncology*. 2019;16:7.
219. Muhsen K, Sinnereich R, Beer-Davidson G, Nassar H, Ahmed WA, **Cohen D**, Kark JD. Correlates of infection with *Helicobacter pylori* positive and negative cytotoxin-associated gene A phenotypes among Arab and Jewish residents of Jerusalem. *Epidemiology & Infection*. 2019;147:e276.
220. Sagie S, Naamnih W, Frej J, **Cohen D**, Alpert G, Muhsen K. Correlates of hospitalizations in internal medicine divisions among Israeli adults of different ethnic groups with hypertension, diabetes and cardiovascular diseases. *PloS one*. 2019;14(4):16.
221. Armon R, Frenkel M, **Cohen D**, Segal E. Dermatomyces in the Israeli defense forces- Epidemiological and clinical aspects. *Mycoses*. 2020;63(1):65-70.
222. Mazaba ML, Siziya S, Monze M, **Cohen D**. Epidemiology of acute rubella infection in Zambia during the pre-vaccination period (2005-2016) as a baseline for monitoring rubella epidemiology in the post-rubella vaccine introduction era. *BMC infectious diseases*. 2020;20(1):7.
223. Muhsen K, Na'amnih W, Adler A, Carmeli Y, **Cohen D**. *Clostridium difficile*-associated disease and *Helicobacter pylori* seroprevalence: A case-control study. *Helicobacter*. 2020;25(1):6.
224. Bassal R, Indenbaum V, Pando R, Levin T, Shinar E, Amichay D, Barak M, Ben-Dor A, Haim AB, Mendelson E, **Cohen D**, Shohat T. Seropositivity of measles antibodies in the Israeli population prior to the nationwide 2018 - 2019 outbreak. *Hum Vaccin Immunother*. 2020;29:1-5.
225. Maor Y, **Cohen D**, Paran N, Israely T, Ezra V, Axelrod O, Shinar E, Izak M, Rahav G, Rahimi-Levene N, Bazofin BM, Gelman R, Dicker D, Brosh-Nissimov T, Megged O, Dahan D, Benov A, Paz A, Edward K, Moran A, Rogowski O, Sorkine P, Mayo A, Zimhony O, Chen J. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. *EClinicalMedicine*. 2020;26
226. Na'amnih W, Carmeli Y, Asato V, Goren S, Adler A, **Cohen D**, Muhsen K. Enhanced Humoral Immune Responses against Toxin A and B of *Clostridium difficile* is Associated with a Milder Disease Manifestation. *J Clin Med*. 2020;9(10):3241.
227. Munitz A, Edry-Botzer L, Itan M, Tur-Kaspa R, Dicker D, Marcoviciu D, Goren MG, Mor M, Lev S, Gottesman T, Muhsen K, **Cohen D**, Stein M, Qimron U, Freund NT, Wine Y, Gerlic M. Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature. *Scientific reports*. 2021;11(1):1-3.
228. Bassal R, **Cohen D**, Green MS, Keinan-Boker L. The Israel National Sera Bank: Methods, Representativeness, and Challenges. *Int J Environ Res Public Health*. 2021;18(5):2280.
229. Bassal R, Keinan-Boker L, **Cohen D**. A Significant Decrease in the Incidence of Shigellosis in Israel during COVID-19 Pandemic. *Int J Environ Res Public Health*. 2021;18(6):3070.
230. Izak M, Yahalom V, Maor Y, Zimhoni O, **Cohen D**, Chen J, Shinar E. COVID-19 - Blood groups, antibodies and convalescent plasma. [HEBREW]. *Harefuah*. 2021;160(3):139-143.

231. **Cohen D**, Atsmon J, Artaud C, Meron-Sudai S, Gougeon M-L, Bialik A, Goren S, Asato V, Ariel-Cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against *Shigella flexneri 2a* in healthy adult volunteers: a phase 1, dose escalating, single-blind, randomised, placebo-controlled study. *Lancet Infect Dis*. 2021;21(4):546-558.
232. Chisenga CC, Bosomprah S, Simuyandi M, Mwila-Kazimbaya K, Chilyabanyama ON, Laban NM, Bialik A, Asato V, Meron-Sudai S, Frankel G, **Cohen D**, Chilengi R. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study. *PLoS One*. 2021;16(5):e0252222.
233. Bassal R, Indenbaum V, Pando R, Levin T, Shinar E, Amichay D, Barak M, Ben-Dor A, Haim AB, Mendelson E, **Cohen D**, Shohat T. Seropositivity of measles antibodies in the Israeli population prior to the nationwide 2018 - 2019 outbreak. *Hum Vaccin Immunother*. 2021;4;17(5):1353-1357.
234. Chodick G, Tene L, Patalon T, Gazit S, Ben Tov A, **Cohen D**, Muhsen K. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. *JAMA Netw Open*. 2021;4(6):e2115985.
235. Muhsen K, Schwaber MJ, Bishara J, Kassem E, Atamna A, Na'amnih W, Goren S, Bialik A, Mohsen J, Zaide Y, Hazan N, Ariel-Cohen O, Cohen R, Shitrit P, Marchaim D, Benenson S, Ben-David D, Rubinovitch B, Gotessman T, Nutman A, Wiener-Well Y, Maor Y, Carmeli Y, **Cohen D**. Sero-Prevalence and Sero-Incidence of Antibodies to SARS-CoV-2 in Health Care Workers in Israel, Prior to Mass COVID-19 Vaccination. *Front Med (Lausanne)*. 2021;8:689994.
236. Muhsen K, Na'aminh W, Lapidot Y, Goren S, Amir Y, Perlman S, Green MS, Chodick G, **Cohen D**. A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020-February 2021. *Lancet Reg Health Eur*. 2021;7:100130.
237. Iflah M, Kassem E, Rubinstein U, Goren S, Ephros M, **Cohen D**, Muhsen K. Convulsions in children hospitalized for acute gastroenteritis. *Scientific Reports*. 2021;11(1):1-8.
238. Muhsen K, **Cohen D**. COVID-19 vaccination in Israel. *Clinical Microbiology and Infection*. 2021;27(11):1570-4.
239. Lapidot Y, Reshef L, **Cohen D**, Muhsen K. Helicobacter pylori and the intestinal microbiome among healthy school-age children. *Helicobacter*. 2021;26(6):e12854.
240. MacLennan CA, Talaat KR, Kaminski RW, **Cohen D**, Riddle MS, Giersing BK. Critical needs in advancing Shigella vaccines for global health. *The Journal of Infectious Diseases*. 2022;225(9):1500-3.
241. Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, Weil C, Goldshtein I, Twig G, **Cohen D**, Muhsen K. The effectiveness of the Two-Dose BNT162b2 vaccine: analysis of real-world data. *Clin Infect Dis*. 2022;74(3):472-8.
242. Izak M, Gendelman V, Bransburg-Zabary S, Stoyanov E, Gat R, **Cohen D**, Chen J, Maor Y, Benov A, Lev B, Zimhony O, Shinar E. Qualifying coronavirus disease 2019 convalescent plasma donors in Israel. *Vox Sang*. 2022;117(2):185-92.

243. Yahalom-Ronen Y, Erez N, Fisher M, Tamir H, Politi B, Achdout H, Melamed S, Glinert I, Weiss S, Cohen-Gihon I, Israeli O..., **Cohen D**,...Paran N. Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera. *Vaccines*. 2022;10(2):291.
244. Mathur S, Banai M, **Cohen D**. Natural *Brucella melitensis* Infection and Rev. 1 Vaccination Induce Specific Brucella O-Polysaccharide Antibodies Involved in Complement Mediated Brucella Cell Killing. *Vaccines*. 2022;10(2):317.
245. Edelman-Klapper H, Zittan E, Shitrit AB, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y...**Cohen D**, Dotan I, REsponses to COVid-19 vaccinE IsRaeli IBD group (RECOVER). Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα. *Gastroenterology*. 2022;162(2):454-67.
246. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, Herzel E, Alapi H, **Cohen D**, Muhsen K, Chodick G, Patalon T. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine: A Retrospective Cohort Study. *Annals of Internal Medicine*. 2022;175(5):674-81.
247. Lapidot Y, Reshef L, Maya M, **Cohen D**, Gophna U, Muhsen K. Socioeconomic disparities and household crowding in association with the fecal microbiome of school-age children. *NPJ biofilms and microbiomes*. 2022;8(1):1-2.
248. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, Herzel E, Alapi H, **Cohen D**, Muhsen K, Chodick G, Patalon T. SARS-CoV-2 Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: a Retrospective Cohort Study. *Clinical Infectious Diseases*. 2022;75(1):e545-e551.
249. Bassal R, Shohat T, Levin T, Pando R, Shinar E, Amichay D, Barak M, Ben-Dor A, Bar-Haim A, Mendelson E, **Cohen D**, Keinan-Boker L, Indenbaum V. The Concordance between Mumps and Rubella Sero-Positivity among the Israeli Population in 2015. *Vaccines*. 2022;10(7):996.
250. Muhsen K, Maimon N, Mizrahi A, Bodenheimer O, **Cohen D**, Maimon M, Grotto I, Dagan R. Effectiveness of BNT162b2 mRNA coronavirus disease 2019 (covid-19) vaccine against acquisition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers in long-term care facilities: a prospective cohort study. *Clinical Infectious Diseases*. 2022;75(1):e755-63.
251. Rabinowitz KM, Navon M, Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H...**Cohen D**,...on behalf of the Responses to COVID-19 Vaccine Israeli IBD Group. Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. *Vaccines*. 2022;10(8):1186.
252. Meron-Sudai S, Reizis A, Goren S, Bialik A, Hochberg A, **Cohen D**. Pentraxin 3 and Shigella LPS and IpaB Antibodies Interplay to Defeat Shigellosis. *Journal of Clinical Medicine*. 2022;11(15):4384.
253. Muhsen K, Maimon N, Mizrahi AY, Varticovski B, Bodenheimer O, **Cohen D**, Dagan R. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2

- Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021. *JAMA Netw Open*. 2022;5(7):e2219940.
254. Muhsen K, Maimon N, Mizrahi AY, Boltyansky B, Bodenheimer O, Diamant ZH, Gaon L, **Cohen D**, Dagan R. Association of receipt of the fourth BNT162b2 dose with omicron infection and COVID-19 hospitalizations among residents of long-term care facilities. *JAMA Internal Medicine*. 2022;182(8):859-67.
 255. **Cohen D**, Ashkenazi S, Schneerson R, Farzam N, Bialik A, Meron-Sudai S, Asato V, Goren S, Baran TZ, Muhsen K, Gilbert PB, MacLennan CA. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data. *Clinical Microbiology and Infection*. 2022;29(3):366-71.
 256. Bassal R, Keinan-Boker L, **Cohen D**, Mendelson E, Lustig Y, Indenbaum V. Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021. *Vaccines*. 2022;10(10):1663.
 257. Avni Biron I, Maayan Y, Mishael T, Hadar E, Neeman M, Plitman Mayo R, Sela HY, Yagel S, Goldenberg R, Ben Ya'acov A, Grisaru Granovsky S, Ollech JE, Edelman-Klapper H, Rabinowitz KM, Pauker MH, Yanai H, Goren S, **Cohen D**, Dotan I, Bar-Gil Shitrit A. SARS-CoV-2 IgG Antibody Levels in Women with IBD Vaccinated during Pregnancy. *Vaccines*. 2022;10(11):1833.
 258. Mathur S, Bardenstein S, **Cohen D**, Banai M. Serum PCR Diagnosis of Brucella melitensis Infection in Rev. 1 Vaccinated Sheep. *Microbiology Research*. 2023;14(1):21-33.
 259. Donkor ES, Muhsen K, Johnson SAM, Kotey FCN, Dayie NTKD, Tetteh-Quarcoo PB, Tette EMA, Osei M-M, Egyir B, Nii-Trebi NI, Owusu-Okyere G, Owusu-Ofori A, Amir Y, Perlman S, Lopes PH, Mfodwo A, Gordon NC, Gresham L, Smolinski M, **Cohen D**. Multicenter Surveillance of Antimicrobial Resistance among Gram-Negative Bacteria Isolated from Bloodstream Infections in Ghana. *Antibiotics*. 2023;12(2):255.
 260. **Cohen D**, Izak M, Stoyanov E, Mandelboim M, Perlman S, Amir Y, Goren S, Bialik A, Kliker L, Atari N, Yishai R, Zaide Y, Marcus H, Madar-Balakirski N, Israely T, Paran N, Zimhony O, Shinar E, Maor Y, Muhsen K. Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic. *International Journal of Infectious Diseases*. 2023;132:72-9.
 261. Miti S, Chilyabanyama ON, Chisenga CC, Chibuye M, Bosomprah S, Mumba C, Chitondo S, Siziya S, **Cohen D**, Chilengi R, Simuyandi M. Sensitivity and predictive value of dysentery in diagnosing shigellosis among under five children in Zambia. *Plos one*. 2023;18(2):e0279012.
 262. Meron-Sudai S, Asato V, Adler A, Bialik A, Goren S, Ariel-Cohen O, Reizis A, Mulard LA, Phalipon A, **Cohen D**. A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults. *npj Vaccines*. 2023;8(1):35.
 263. Bassal R, Davidovich-Cohen M, Yakunin E, Rokney A, Ken-Dror S, Strauss M, Wolf T, Sagi O, Amit S, Moran-Gilad J, Treygerman O, Karyo R, Keinan-Boker L, **Cohen D**. Trends in the Epidemiology of Non-Typhoidal Salmonellosis in Israel between 2010 and 2021. *International Journal of Environmental Research and Public Health*. 2023;24;20(9):5626.
 264. Lapidot Y, Maya M, Reshef L, **Cohen D**, Ornoy A, Gophna U, Muhsen K. Relationships of the gut microbiome with cognitive development among healthy school-age children. *Frontiers in Pediatrics*. 2023;11:1198792.

265. Mazaba ML, Bosomprah S, **Cohen D**, Monze M, Siziya S. Estimated incidence and transmission intensity of rubella infection in Zambia pre-vaccine era 2005–2016. *Epidemiology & Infection*. 2023;151:e9.
266. Maor Y, Shinar E, Izak M, Rahav G, Brosh-Nissimov T, Kessler A, Rahimi-Levene N, Benin-Goren O, **Cohen D**, Zohar I, Alagem N, Castro S, Zimhony O. A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019. *Clinical Infectious Diseases*. 2023:ciad305.
267. Edelman-Klapper H, Rabinowitz KM, Zittan E, Shitrit AB, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberga A, Levy-Barda A, Broitman Y, Ben Zvi H, Perets TT, Eliakim R, Barkan R, Goren S, **Cohen D**, Dotan I. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases. *Vaccines*. 2023;20;11(7):1263.

BOOKS

1. Green M, Zenilman J, **Cohen D**, Wisner I, Balicer R. Risk Assessment and Risk Communication Strategies in Bioterrorism Preparedness. Dordrecht: Springer. 2007.

CHAPTERS

1. **Cohen D**, Ashkenazi, S, Green M, Gdalevich M, Yavzori M, Orr N, Robin G, Slepion R, Lerman Y, Block C, Ashkenazi I, Taylor D, Hale L, Sadoff J, Schneerson R, Robbins J, Wiener M, Shemer J. Clinical trials of Shigella vaccines in Israel. Chapter 21: "Novel strategies in the design and production of vaccines". In: Advances in Experimental Medicine and Biology. Eds. Cohen S and Shafferman A. Plenum Press. New York and London. 1996:397:159-167.
2. Boxman RL, Parkansky N, Mamane H, Meirovitz M, Orkabi Y, Halperin T, **Cohen D**, Orr N, Gidalevich E, Alterkop B, Cheskis S. Pulsed Submerged Arc Plasma Disinfection of Water: Bacteriological Results and an Exploration of Possible Mechanisms. In: Plasma Assisted Decontamination of Biological and Chemical Agents. Eds. Guceri S, Friedman A. Springer 2008: 41-50.

REVIEWS

1. Ashkenazi S, **Cohen D**. An update on Shigella vaccines. *Isr J Med Sci*. 1994;30(5-6):495-7.
2. Wisner I, Balicer RD, **Cohen D**. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. *Vaccine*. 2007;25(6):976-84.
3. Ashkenazi S, **Cohen D**. An update on vaccines against Shigella. *Therapeutic advances in vaccines*. 2013;1(3):113-23.
4. Shmueli H, Domniz N, **Cohen D**. Probiotics in the prevention of colorectal cancer. *Current Colorectal Cancer Reports*. 2013;9(1):31-6.
5. Bassal R, Schejter E, **Cohen D**, Keinan-Boker L. Implementation of a national program for early detection of pre malignant and malignant cervical morbidity in Israel [HEBREW]. *Harefuah*. 2017;156 (1):51-53.
6. Muhsen K, **Cohen D**. Rotavirus vaccines in Israel: uptake and impact. *Human Vaccines & Immunotherapeutics*. 2017;13(7):1722-7.
7. Green MS, LeDuc J, **Cohen D**, Franz DR. Confronting the threat of bioterrorism: realities, challenges and defensive strategies. *Lancet Inf Dis*. 2019;19(1):e2-e13

8. **Cohen D**, Meron-Sudai S, Bialik A, Asato V, Ashkenazi S. Detoxified O-Specific Polysaccharide (O-SP)–Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene. *Vaccines*. 2022;10(5):675.

LETTERS

1. Levine MM, **Cohen D**, Green M, Levine OS, Mintz ED. Fly control and shigellosis. *Lancet*. 1999;353(9157):1020
2. Hasin T, Davidovitch N, **Cohen D**. The authors reply. *New England Journal of Medicine*. 2006;355(15):1614-5.
3. Muhsen K, Shulman L, **Cohen D**. Norovirus in patients with gastroenteritis. *Lancet Infect Dis*. 2015;15(5):508.
4. Muhsen K, Maimon N, Mizrahi A, Varticovski B, Bodenheimer O, Gelbshtein U, Grotto I, **Cohen D**, Dagan R. Effects of BNT162b2 Covid-19 vaccine booster in long-term care facilities in Israel. *New England Journal of Medicine*. 2022;386(4):399-401.
5. **Cohen D**. More on the Global Burden of Shigellosis. *Romanian Archives of Microbiology and Immunology*. 2022;81(2):77-78

PROCEEDINGS

1. Dinari G, **Cohen DI**, Rouach T, Ferne M, Fleiderman S, Rabinowitz SB. Food-borne epidemic of group C followed by group A M-49 streptococcal pharyngitis in an Israeli military base. *Adv Pathol*. 1982;1:69-72.
2. Ferne M, Fleiderman S, Rouach T, **Cohen DI**, Dinari G, Rabinowitz SB. An outbreak of pharyngitis due to group C streptococci in a military camp. Antibody response to cellular and extracellular antigens. *Adv Pathol*. 1983;1:65-72.
3. **Cohen D**, Rouach T, Michaeli D, Ofek I. A seroepidemiological study of shigellosis among military recruits. Proceedings of the Fourth Mediterranean Congress of Chemotherapy. Rhodes, Greece. 19-25 Oct 1984.
4. Ferne M, **Cohen DI**, Rouach T, Dinari G, Rabinowitz SB. Food-borne epidemics of group A, C and G streptococcal pharyngitis in Israeli military camps. Proceedings of the 9th Lancefield International Symposium on streptococci and streptococcal diseases. Japan. 10-13 Sept 1985
5. **Cohen D**, Green MS, Block C, Rouach T, Ofek I, Swartz T, Lowell G, Tramont E. Assessment of antibody screening in selection of subjects for field trials of Shigella vaccines. *Annali Sclavo Collana monografica*. 1986;3(1-2):151-4.
6. Schwartz D, Melamed I, Spiner Z, **Cohen DI**, Konforti N, Goldhar J. ELISA for C. jejuni antibodies in Israeli children and soldiers. Proceedings of the 16th International Congress of Chemotherapy. Jerusalem, Israel. 1989:515.1-515.2.
7. Boxman RL, Parkansky N, Mamane H, Meirovitz M, Orkabi Y, Halperin T, **Cohen D**, et al. Pulsed submerged arc plasma disinfection of water: Bacteriological results and an exploration of possible mechanisms. In: NATO Security through Science Series. Chemistry and Biology 2008: p. 41-50.

SCIENTIFIC PRESENTATIONS AND ABSTRACTS

1. Feingold A, **Cohen D**, Rouach T. Normal distribution of anti-streptozyme (ASTZ) titers in a reference healthy population [abstract]. In: 1st International Congress of Pediatric Laboratory Medicine. 1980: p.100. Jerusalem, Israel. 12-17 Oct 1980.
2. **Cohen D**, Ferne M, Rabinowitz SB, Feingold A, Rouach T. Distribution of streptococcal antibodies in a random sample of Israeli soldiers [abstract]. In: Isr J Med Sci. January 1981.
3. **Cohen DI**, Rouach T, Dinari G, Ferne M, Fleiderman S, Rabinowitz SB. Food-borne epidemic of group C streptococcal pharyngitis in an Israeli military base [abstract]. In: Isr J Med Sci. 1982.
4. Ferne M, Fleiderman S, Rouach T, **Cohen D**, Dinari G, Rabinowitz SB. Dynamics of immune response to extracellular and somatic antigens in an outbreak of pharyngitis caused by group C streptococci [abstract]. In: Isr J Med Sci. 1982;18:13
5. **Cohen DI**, Rouach T, Kark JD, Rabinowitz SB. A survey of streptococcal infection in female military recruits. Preliminary report [abstract]. In: Isr J Med Sci. 1983;19: 687
6. **Cohen DI**, Green M, Block C, Rouach T, Ofek I. Persistence of anti-Shigella lipopolysaccharide (LPS) humoral antibodies after shigellosis [abstract and poster presentation]. In: International Symposium on the Immunology of the Gastrointestinal Tract and the Liver Jerusalem, Israel. 22-27 Mar 1987.
7. Ben-Yehuda O, **Cohen D**, Alkan M, Green M, Jelin N, Steinhertz R. Effectiveness of doxycycline prophylaxis for shigellosis [abstract]. In: The 27th ICAAC. 1987: p.146. New York, NY. 4-7 Oct 1987.
8. Davidsohn Y, **Cohen DI**, A. Vansover, and Block C. Plasmid profiles of shigellas isolated from epidemic and sporadic cases of shigellosis. In: Annual Meeting of the of the Israel Society Microbiol. 1988: p. 79.
9. **Cohen D**, Green M, Block C, Slepon R, Dotan K, Levine M. Fly-control and attack rate of shigellosis in military field units [abstract]. In: Annual Conference of the Israel Society Epidemiol. 1989: p. 5.
10. Ozbonfil D, **Cohen D**, Sechter I, Rouach T, Lev B. An outbreak of enteritis caused by Enteroinvasive E. coli in an Israeli military base [abstract]. In: Annual Meeting of the Israel Society Microbiol. 1989: p. 45.
11. Gillis D, Beck A, **Cohen D**, Rouach T, Karsenty E, Green M, Katzenelson E. Foodborne epidemic of group A streptococcal pharyngitis caused by a probable new serotype [abstract]. In: Annual Meeting of the Israel Society Microbiol. 1989: p. 9.
12. Green M, **Cohen D**, Zaide Y, Slepon R, Danon Y. Trends in the prevalence and correlates of previous Hepatitis A infection in Israel [abstract]. In: European Society against Virus Diseases Joint Meeting. Groningen, Netherlands. 18-22 June 1989.
13. Green M, Handsher R, **Cohen D**, Slepon R, Rannon L, Danon Y. Serum antibody titers against type 1 Poliovirus in young adults in Israel prior to the 1988 outbreak [abstract]. In: European Society against Virus Diseases Joint Meeting. Groningen, Netherlands. 18-22 June 1989.
14. Yavzori M, **Cohen D**, Bercovier H. Molecular epidemiology of Shigella infections occurring among Israeli soldiers. In: US/IDF Conference on Infectious Diseases and Vaccines of Military Importance. Gaithersburg, Maryland. 17-20 June 1990.

15. Lowell G, Robin G, **Cohen D**, Keren D, formal S, Sadoff J, Green M, Danon Y. Antibody-dependent cell-mediated anti-Shigella activity by human peripheral blood lymphocytes and monocytes with convalescent sera or immune intestinal secretory IgA. In: US/IDF Conference on Infectious Diseases and Vaccines of Military Importance. Gaithersburg, Maryland. 17-20 June 1990.
16. Zaide Y, Karasenty E, Ksaizak TG, Peters CJ, LeDuc J, **Cohen D**, Slepon R, Rouach T, Danon Y. Presence of antibodies to various arboviruses among Israeli reserve soldiers. In: US/IDF Conference on Infectious Diseases and Vaccines of Military Importance. Gaithersburg, Maryland. 17-20 June 1990.
17. **Cohen D**, Katzenelson E, Green M, Slepon R, Bercovier H, Danon Y. Prevalence and correlates of anti-diphtheria toxin antibodies among young adults in Israel [abstract]. In: Annual Conference of the Israel Society Microbiol. 1991: p. 5.
18. **Cohen D**, Yavzori M, Orr N, Ambar R, Shohat T, Heering S, Block C, Treistman J, Mates A, Lerman Y. A cluster of cases of dysentery caused by *S.dysenteriae* type 1 in a military base [abstract]. In: Annual Meeting of the Israel Society Microbiol. 1991: p. 10.
19. Yavzori M, **Cohen D**, Bercovier H. Molecular epidemiology of Shigella infections in Israel. In: *Isr J Med Sci*. 1991 27:416-417.
20. **Cohen D**, Katzenelson E, Green M, Slepon R, Bercovier H, Danon Y. Prevalence and correlates of anti-diphtheria toxin antibodies among young adults in Israel. In: The 8th Israel Medical Week. Medax 91. Jerusalem, Israel. 4-7 Nov 1991.
21. **Cohen D**, Green M, Block C, Slepon R, Lerman Y. Evidence that factors additional to serum anti-LPS antibodies are associated with naturally acquired immunity to shigellosis. In: The 8th Israel Medical Week. Medax 91. Jerusalem, Israel. 4-7 Nov 1991.
22. Yavzori M, Bercovier H, **Cohen D**. Molecular epidemiologic techniques in analysis of an unusual cluster of cases of Shiga dysentery in Israel [abstract]. In: Annual Conference of the Israel Society Microbiol. 1992: p. 18.
23. **Cohen D**, Yavzori M, Ambar R, Slepon R. Laboratory diagnosis of bacterial enteric infections: The old and the new [abstract]. In: Annual Meeting of the Israel Society Microbiol. 1992: p. 27.
24. Robin G, Orr N, Keisari Y, Lowell G, **Cohen D**. Markers of natural and induced immunity to Shigella [abstract]. In: Annual Meeting of the Israel Society Microbiol. 1992: p. 31.
25. Orr N, Robin G, Aboud-Pirac E, **Cohen D**, Lowell G. Shigella LPS complexed to proteosomes: A new approach for vaccine delivery [abstract]. In: Annual Meeting of the Israel Society Microbiol. 1992: p. 30.
26. Sechter I, **Cohen D**. Phages-types of Shigella sonnei in Israel [abstract]. In: Annual Meeting of the Israel Society Microbiol. 1992: p. 74.
27. **Cohen D**. Characteristics of foodborne transmission of infectious agents in Israeli military units [abstract]. In: International Conference of Foodservice Systems beyond the Year 2000. Jerusalem, Israel. 29-31 Mar 1992. 1992: p. 9.
28. **Cohen D**, Green MS, Block C, Slepon R, Lerman Y. Natural immunity to shigellosis is only partially expressed by serum anti-LPS antibodies. In: *Vaccines* 1992 10:284.

29. Orr N, Robin G, Aboud-Pirac E, **Cohen D**, Lowell G. Oral or intranasal immunization with Shigella LPS complexed to proteosomes induces intestinal and serum IgA and IgG. In: Vaccines 1992 10:276.
30. Green M, **Cohen D**, Lerman Y, Sjogren M, Binn L, Tsur S, Slepon R, Robin G, Hoke C, Danon Y. A trial of the immunogenicity of inactivated hepatitis A vaccine administered with immune serum globulin. In: Vaccine 1992 10:291.
31. Green MS, **Cohen D**, Lerman Y, Ashkenazi S, Tsur S, Robin G, Wiener M. Etiology of viral hepatitis in the Israel Defense force between 1989-1991. In: The US/IDF Medical Research Conference. Annapolis, Maryland. 1-6 Nov 1992.
32. Ashkenazi S, **Cohen D**, Lerman Y, Slepon R, Green M. Trends in the incidence of shigellosis in military and civilian populations in Israel. In: The US/IDF Medical Research Conference. Annapolis, Maryland. 1-6 Nov 1992.
33. Robin G, **Cohen D**, Ambar R, Slepon R, Ashkenazi S, Keisary Y. IgG subclass distribution of the anti-LPS antibody response following Shigella natural infection. In: The US/IDF Medical Research Conference. Annapolis, Maryland. 1-6 Nov 1992.
34. Lowell G, Orr N, Mallett C, Robin G, Arnon R, formal S, **Cohen D**, Hale T. Oral or intranasal proteosome - Shigella sonnei LPS vaccines: Immunogenicity and protection against keratoconjunctivitis in guinea pigs and against lethal pneumonia in mice. In: The US/IDF Medical Research Conference. Annapolis, Maryland. 1-6 Nov 1992.
35. Orr N, Robin G, **Cohen D**, Arnon R, Lowell G. S.flexneri 2a LPS - proteosome hydrophobic complex elicited strong immune response in mice and induced protection against intraocular challenge in guinea pigs. In: The US/IDF Medical Research Conference. Annapolis, Maryland. 1-6 Nov 1992.
36. Green M, **Cohen D**, Sjogren M, Binn L, Slepon R, Robin G, Hoke C, Bankroft WH, Danon Y, Wiener M. Twelve-month follow-up of the immunogenicity of a hepatitis A vaccine administered alone or with immune serum globulin. In: The US/IDF Medical Research Conference. Annapolis, Maryland. 1-6 Nov 1992.
37. **Cohen D**, Ashkenazi S, Green M, Lerman Y, Robin G, Slepon R, Heller R, Block C, Schneerson R, Robbins J, Wiener M. Safety and immunogenicity study of Shigella flexneri and Shigella sonnei conjugate vaccines among Israeli soldiers (Preliminary results). In: The US/IDF Medical Research Conference. Annapolis, Maryland. 1-6 Nov 1992.
38. **Cohen D**, Ashkenazi S, Green M, Yavzori M, Orr N, Lerman Y, Ambar R, Block C, Taylor D, Hale T, formal S, Sadoff J, Wiener M. Safety and immunogenicity of the oral E.coli K12-S.flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers. In: The US/IDF Medical Research Conference. Annapolis, Maryland. 1-6 Nov 1992.
39. **Cohen D**, Ashkenazi S, Green M, Lerman Y, Block C, et al. Acceptibility and immunogenicity studies of Shigella vaccines in Israel. In: Regional European Meeting of the International Epidemiological Association. Jerusalem, Israel. 14-19 Feb 1993.
40. Ashkenazi S, **Cohen D**, May-Zahav M, Slepon R, Green M. Changing epidemiology of Shigella species in hospitalized and ambulatory patients. In: Regional European Meeting of the International Epidemiological Association. Jerusalem, Israel. 14-19 Feb 1993.

41. Lerman Y, Slepon R, **Cohen D**. The epidemiology of acute diarrheal diseases in children in a communal settlement in Israel. In: Regional European Meeting of the International Epidemiological Association. Jerusalem, Israel. 14-19 Feb 1993.
42. **Cohen D**, Ashkenazi S, Green MS, Gdalevich M, Yavzori M, Robin G, Slepon R, Orr N, Ambar R, Lerman Y, Block C, Schneerson R, Robbins J, Taylor D, Hale T, Sadoff J, Wiener M. Field Evaluation of the Oral E.coli K12 S.flexneri 2a and Parenteral S.sonnei Conjugate Vaccines among Israeli Soldiers: Progress Report. In: The 6th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Herzliya, Israel. 24-25 Jan 1994.
43. Green MS, **Cohen D**, Ashkenazi S, Lerman Y, Binn L, Slepon R, Robin G, Hoke C, Bancroft WH, Wiener M. Experience with the New Inactivated Hepatitis A Virus Vaccines: Implications for Vaccination Policy in Military Populations. In: The 6th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Herzliya, Israel. 24-25 Jan 1994.
44. **Cohen D**, Ashkenazi S, Green MS, Lerman Y, Slepon R, Robin G, Ambar R, Heller R, Block C, Schneerson R, Robbins J, Wiener M. Safety and Immunogenicity of One and Two Doses of Shigella flexneri 2a and Shigella sonnei Conjugate Vaccines among Israeli Soldiers. In: The 6th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Herzliya, Israel. 24-25 Jan 1994.
45. **Cohen D**, Orr N, Robin G, Marcus I, Slepon R, Low M, Zaide Y, Ashkenazi S. Detection of anti-Shigella LPS antibodies in urine following natural infection and immunization with oral and parenteral Shigella vaccines. In: The 6th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Herzliya, Israel. 24-25 Jan 1994.
46. Yavzori M, I. Hakim, Amariglio N, Ashkenazi S, **Cohen D**, Rechavi G. Application of denaturing gradient gel electrophoresis for differentiation of Shigella species. In: The 6th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Herzliya, Israel. 24-25 Jan 1994.
47. Lowell G, Kaminski R, Mallett C, Orr N, Hartman A, **Cohen D**, Amselem S, Echeverria P, Hale T. Progress in the development of intranasal and oral proteosome Shigella vaccines. In: The 6th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Herzliya, Israel. 24-25 Jan 1994.
48. Lerman Y, Slepon R, Yavzori M, Ambar R, Sechter I, **Cohen D**. Epidemiology of acute diarrhea in a communal settlement. In: The 6th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Herzliya, Israel. 24-25 Jan 1994.
49. Kark J, Orr N, Slepon R, **Cohen D**. Helicobacter pylori infections in Israel: Prevalence at age 18 and incidence during military service. In: The 6th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Herzliya, Israel. 24-25 Jan 1994.
50. Yavzori M, Wasserlauf R, Ambar R, Block C, Ashkenazi S, **Cohen D**. Direct detection of enterotoxigenic E.coli in stool specimens by Polymerase Chain Reaction. In: Annual Meeting of the Israel Society Microbiol. Rehovot, Israel. 14-15 Feb 1994.
51. Ephros M, Ashkenazi S, **Cohen D**, Yavzori M, Rotman N, Novic B. Encephalopathy associated with cytotoxin-producing enteroinvasive E.coli. In: Annual Meeting of the Israel Society Microbiol. Rehovot, Israel. 14-15 Feb 1994.

52. Law M, Almog R, Samuels Y, Robin G, **Cohen D**, Ashkenazi S, Bercovier H, Gdalevich M, Green M. Prevalence of antibodies against hepatitis A, B and C viruses among new immigrants from the former U.S.S.R. to Israel in the years 1990-91. In: Annual Meeting of the Israel Society for Epidemiol. Jerusalem, Israel. 5 April 1994.
53. **Cohen D**. The immune response to Shigella induced by natural infection and candidate vaccines. In: The 6th GIF Meeting on Host-Pathogen Interaction. Greifswald, Germany. 29 May - 2 Jun 1994.
54. **Cohen D**. New strategies in the development of enteric vaccines. In: Symposium of the Israeli Society for Infectious Diseases on "New strategies in development of vaccine". Ganei-Hataaruha, Tel Aviv. 26 Jan 1995.
55. Lowell G, Echeverria P, Mallet C, Corcoran K, Kaminski R, Orr N, Marsh M, Schobitz E, **Cohen D**, Young GD, Hale T. Mucosal immunogenicity in non-human primates of proteosome-Shigella sonnei lipopolysaccharide vaccines. In: American Society for Microbiology (ASM) Annual Meeting. Washington, DC. 17-21 May 1995.
56. Mallett C, Hodur DM, Schobitz E, Kaminski R, Orr N, **Cohen D**, Lowell G, Hale T. Efficacy and immunogenicity studies of mucosal proteosome-Shigella LPS vaccines in a murine intranasal challenge model of Shigella infection. In: The 9th International Congress of Immunology. Bethesda, MD. Apr 1995.
57. **Cohen D**, Orr N, Yavzori M, Robin G, Ashkenazi S. New strategies in the development of Shigella vaccines. In: Annual Meeting of the Israel Society Microbiol. Technion, Haifa, Israel. 6-7 Feb 1995.
58. **Cohen D**, Robin G, Slepon R, Marcus I, Ashkenazi S, Orr N. Shigella sonnei LPS antibodies in urine after natural infection or vaccination. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 17-20 Sep 1995. San Francisco, CA. 1995: p. 167.
59. **Cohen D**, Ashkenazi S, Green M, Gdalevich M, Yavzori M, Slepon R, Robin G, Orr N, Ashkenazi I, Shemer J, Taylor D, Sadoff J, Schneerson R, Robbins J. Safety, immunogenicity and efficacy of a Shigella-O specific polysaccharide conjugate vaccine in Israeli volunteers. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 17-20 Sep 1995. San Francisco, CA. 1995: p. 159.
60. Yavzori M, Porat N, Dagan R, Wasserlauf R, **Cohen D**, Detection of enterotoxigenic E. coli (ETEC) in stool specimens by polymerase chain reaction (PCR). In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 17-20 Sep 1995. San Francisco, CA. 1995: p. 81.
61. **Cohen D**, Ashkenazi S, Green M, Gdalevich M, Yavzori M, Orr N. Robin G, Slepon R, I. Lerman, Block C, Ashkenazi I, Taylor D, Hale T, Sadoff J, Schneerson R, Robbins J, Shemer J. Clinical trials of Shigella vaccines in the IDF. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
62. **Cohen D**, Orr N, Sela T, Ashkenazi S, Slepon R, Green M, Yavzori M, Robin G, Ashkenazi I, Trofa A, Taylor D, Svennerholm A, Shemer J. Outpatient study on the safety and immunogenicity of a formalin-killed whole cell plus B subunit (ETEC/rBS) enterotoxigenic Escherichia coli vaccine (Oral ETEC Vaccine) in healthy, Israeli, adult volunteers. Seventh

- IDF-USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. 11-14 December, 1995. Gaithersburg, Maryland.
63. Yavzori M, Ashkenazi S, Lerman Y, Ambar R, Bercovier H, **Cohen D**. Molecular epidemiology of Shigella infections in the Israel Defence force. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 64. Yavzori M, Porat N, Dagan R, Wasserlauf R, **Cohen D**. Detection of enterotoxigenic E. coli (ETEC) in stool specimens by Polymerase Chain Reaction. (PCR). In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 65. Orr N, Sela T, Marcus I, **Cohen D**. Modified ELISA for detection of urinary antibodies ETEC and Shigella antigens. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 66. **Cohen D**, Monroe S, Slepion R, Glass RI. Seroepidemiological study of Norwalk virus infections among Israeli soldiers serving in field units. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 67. Robin G, **Cohen D**, Marcus I, Ashkenazi S, Keysari Y. Quantitative and qualitative analysis of serum IgG and IgG subclass response to Shigella natural infection and to vaccination. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 68. Orr N, **Cohen D**, Bercovier H, Arnon R, Lowell G. Development of a bivalent Shigella flexneri 2a/Shigella sonnei vaccine composed of LPS-proteosome hydrophobic complex. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 69. Ashkenazi S, **Cohen D**. Increasing antimicrobial resistance of Shigella isolates in Israel. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 70. Almog R, Low M, Samuels Y, Robin G, **Cohen D**, Ashkenazi S, Bercovier H, Gdalevich M, Green M. Prevalence of antibodies against hepatitis A, B, and C viruses and HBsAg carriage among male immigrants from the previous USSR who arrived in Israel during 1990-1991. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 71. Low M, Almog R, Ashkenazi S, Bercovier H, Katzenelson E, Green M, **Cohen D**. Prevalence and correlates of diphtheria toxin antibodies among immigrants from the previous USSR who arrived in Israel during 1990-1991. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 72. Green MS, Gdalevich M, Sela T, Robin G, Ambar R, Zaide Y, **Cohen D**. Ashkenazi I. Host factors associated with the immune response of health-care workers to hepatitis B vaccine. In: The 7th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Gaithersburg, Maryland. 11-14 Dec 1995.
 73. Orr N, Slepion R, Marcus I, Sela T. **Cohen D**. Use of urinary antibodies as a marker of mucosal stimulation following vaccination with the oral ETEC whole cell killed vaccine. In: The 8th

- IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Jerusalem, Israel. 3-6 Nov 1996.
74. Hounq HH, Yavzori M, Marash M, **Cohen D**, Hale T. Joint development and evaluation of a protocol for detection of *Shigella sonnei* in stool specimens by polymerase chain reaction. In: The 8th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Jerusalem, Israel. 3-6 Nov 1996.
 75. Robin G, Askenazi I, Sela T, Slepon R, Marcus I, Ashkenazi S, Keisari Y, **Cohen D**. Studies on the serum antibody response to *Shigella* LPS after natural infection or vaccination. In: The 8th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Jerusalem, Israel. 3-6 Nov 1996.
 76. Adamsky K, Robin G, Orr N, **Cohen D**, Nissim A. Preliminary data on selection of recombinant antibodies to *Shigella* lipopolysaccharide (LPS) and heat-labile toxin (LT) of ETEC. In: The 8th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Jerusalem, Israel. 3-6 Nov 1996.
 77. **Cohen D**, Sela T, Slepon R, Haim M, Ambar R, Askenazi I, Shemer Y. Incidence rates and characteristics of the *Shigella* and enterotoxigenic *E. coli* infections occurring among Israeli soldiers serving under field conditions. In: The 8th IDF/USAMRDC Conference on Infections Diseases & Vaccines of Military Importance. Jerusalem, Israel. 3-6 Nov 1996.
 78. **Cohen D**. Surveillance on enterotoxigenic *E. coli*-related diarrhea in field units of the Israel Defense force. In: Workshop on Laboratory Assays (ETEC and other) for traveler's diarrhea aetiology surveys and vaccine efficacy trials. Geneva, Switzerland. 22-23 March 1997.
 79. **Cohen D**. Safety and immunogenicity of the oral ETEC whole cell killed vaccine (EOO3) in healthy Israeli volunteers. In: Workshop on Laboratory Assays (ETEC and other) for traveler's diarrhea aetiology surveys and vaccine efficacy trials. Geneva, Switzerland. 22-23 March 1997.
 80. **Cohen D**, Robin G, Orr N, Yavzori M, Porat N, Dagan R, Fraser D, Deckelbaum RJ. Diagnostic approaches to enteric disease pathogens. In: The 6th Annual Meeting for the International Centers for Tropical Disease Research. 5-7 May 1997.
 81. Coster TS, Sansonetti PJ, **Cohen D**, Hale T, VanDeVerg LL, Hartman A, Oaks EV, Venkatesan MM, Hoge CW. Clinical trials of *Shigella flexneri* 2a candidate vaccine SC602. In: Microbial Pathogenesis and Host Defense Conference. New York, NY. 10-14 Sept 1997.
 82. Hale T, Coster TSS, Hoge CW, Mallet C, Hartman A, VanDeVerg LL, **Cohen D**, Lowell G. *Shigella* vaccines: Progress and Prospects. In the 12th World on Animal, Plant and Microbial Toxins. Cuemavaca, Mexico. 21-26 Sept 1997.
 83. Low M, Almog R, Green M, Ashkenazi S, Bercovier H, Katzenelson E, Ashkenazi I, Shemer J, **Cohen D**. Immune status against diphtheria among immigrants from previous USSR who arrived in Israel during 1990-1991. Submitted for publication: *Infection*. Poster presentation. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada. Oct 1997.
 84. **Cohen D**, Yavzori M, Ambar R, Wolk M, Vasilev V, Ephros M. Acute gastroenteritis and extraintestinal complications due to enterovirulent *E. coli*. In: Annual Meeting of the Israel Society Microbiol. 9-10 Feb 1998. Tel Aviv University, Israel. 1998: p.16.

85. Metzger E, Agmon V, **Cohen D**. Emerging salmonellosis due to multiresistant *Salmonella typhimurium* phage-type DT104 in Israel. In: Annual Meeting of the Israel Society Microbiol. 9-10 Feb 1998. Tel Aviv University, Israel. 1998: p. 17.
86. Robin G, Keisari Y, Katzenellenbogen M, **Cohen D**. A high IgG1 to IgG2 anti LPS antibody ratio facilitates the killing of *Shigella* spp. by human phagocytes. In: The 1st Symposium of the Institute on Molecular Genetics of Bacterial Pathogenesis. Ramot, Israel. 6-8 May 1998.
87. Yavzori M, **Cohen D**, Adamsky K, Bercovier H. Expression of foreign adhesion factors in a non-invasive *Shigella* vaccine strain. In: The 1st Symposium of the Institute on Molecular Genetics of Bacterial Pathogenesis. Ramot, Israel. 6-8 May 1998.
88. **Cohen D**. Current strategies in the development of *Shigella* vaccines. In: The 1st Symposium of the Institute on Molecular Genetics of Bacterial Pathogenesis. Ramot, Israel. 6-8 May 1998.
89. LeBlancq S, **Cohen D**, Dagan R, Fraser D, Perz J, Robin G, Widmer G, Deckelbaum RJ. Aspects of *Cryptosporidium parvum* biology. In: The 7th Annual Meeting for the International Centers for Tropical Disease Research. Bethesda, MD. 5-7 May 1998.
90. Hale T, Coster TS, Van De Verg LL, Venkatesan MM, Hartman A, Oaks EV, Taylor DN,
91. **Cohen D**, Robin G, Sansonetti PJ. Human safety and efficacy studies of *Shigella flexneri* 2a SC602 oral vaccine. In: American Society for Microbiology (ASM) Annual Meeting. Atlanta, GA. 17-21 May 1998.
92. Robin G, Fraser D, Sela T, Ambar R, Dagan R, LeBlancq SM, Deckelbaum RJ, **Cohen D**. Prevalence of anti-*Cryptosporidium* antibodies among infants in southern Israel is much higher than predicted from surveillance based on examination of stools. In: American Society for Tropical Medicine and Hygiene (ASTMH) Conference. Oct 1988.
93. **Cohen D**, Monroe SS, Haim M, Yavzori M, Slepon R, Noel J, Estes MK, Glass RII. Norwalk virus infections in Israeli soldiers. In: International Workshop on Human Caliciviruses. Centers for Disease Control and Prevention, Atlanta, GA. 29-31 March 1999.
94. Dagan D, Yavzori M, Orr N, Yohas Y, Meron D, Ashkenazi S, **Cohen D**. A clonal outbreak of nalidixic acid-resistant *Shigella sonnei* shigellosis in northern Israel– epidemiological and molecular analysis. In: The 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco. Sep 1999.
95. Robin G, **Cohen D**, Katzenellenbogen M, Keisari Y. A high IgG1 to IgG2 anti LPS antibody ratio facilitates the killing of *Shigella* spp. by human phagocytes. In: The Batsheva de Rothschild Seminar on Innate Immunity. Zichron Yaakov, Israel. 10-15 Oct 1999.
96. **Cohen D**. Food-borne infections. In: Annual Conference of the Israeli Center for Disease Control. Cfar HaMaccabiah, Israel. 28 Dec 2000.
97. **Cohen D**, Robin G, Orr N, Fraser D. Epidemiologic and Diagnostic Aspects of Human *Cryptosporidiosis*. In: Annual Meeting of the Israeli Society for Microbiology. Ben-Gurion University of the Negev, Beer Sheva, Israel. 26-27 Feb 2001.
98. **Cohen D**. Seroepidemiological studies to monitor the immune status of the Israeli population against vaccine preventable diseases. In: Annual Meeting of the Israeli Center for Diseases Control. Cfar HaMaccabiah, Israel. 15 Nov 2001.
99. **Cohen D**. Laboratory diagnosis of travelers' diarrhea. In: Annual Meeting of the Israeli Society for Microbiology. Hebrew University, Jerusalem, Israel. 20-21 Feb 2002.

100. Green M, Aharonowitz G, Bromberg M, Taich E, Peled T, Kaufmann Z, **Cohen D**, Herman A, Sobel A. Use of simulation techniques to evaluate the efficacy of syndrome surveillance to detect bioterrorist attacks. In: National Syndrome Surveillance Conference. New York, NY. 23-24 Sep 2002.
101. **Cohen D**, Orr N, Sela T, Yavzori M, Kayuf R, Klement E, Ambar R, Hassin T, Engel I, Rogovski O, Ashkenazi S for ETEC Study Group. Phase 3 study of the oral, killed enterotoxigenic E. coli-Cholera toxin B subunit vaccine among volunteers in the Israel Defense forces. In: "Shoresh" Biomedical Meetings. Herzliya, Israel. 5-9 Jan 2003.
102. Tal S, Banet C, Malkinson M, Levi O, Steinman A, Shpigel N, Huerta M, Grotto I, Orr N, **Cohen D**. Serosurveys to assess exposure to West Nile Virus in Israel among human and equine populations. In: "Shoresh" Biomedical Meetings. Herzliya, Israel. 5-9 Jan 2003.
103. Klement E, Srugo Y, **Cohen D** for the Pertussis Study Group. Sporadic and epidemic pertussis in the IDF. In: "Shoresh" Biomedical Meetings. Herzliya, Israel. 5-9 Jan 2003.
104. Bassal R, Ben Ezer Y, Rouach T, Block C, Vasilev V, Agmon V, Green M, **Cohen D**. Identification and characterization of recent Shigella outbreaks – The role of the sentinel laboratory-based surveillance network for enteric bacterial diseases. In: "Shoresh" Biomedical Meetings. Herzliya, Israel. 5-9 Jan 2003.
105. Yavzori M, Houg SH, Katz DE, **Cohen D**, Orr N. Rapid diagnosis of Shigella by using real-time PCR. In: "Shoresh" Biomedical Meetings. Herzliya, Israel. 5-9 Jan 2003.
106. Kayouf R, Klement E, Yavzori M, Ephros M, El-On Y, **Cohen D** for the Leishmania Study Group. Cutaneous Leishmaniasis among recruits serving in an endemic region. In: "Shoresh" Biomedical Meetings. Herzliya, Israel. 5-9 Jan 2003.
107. **Cohen D**, Orr N, Sela T, Yavzori M, Kayuf R, Klement E, Ambar R, Hassin T, Engel I, Rogovski O, Ashkenazi S for the ETEC Study Group [invited lecture]. Phase 3 study of the oral, killed ETEC-cholera toxin B subunit vaccine among volunteers in the Israel Defense forces. Stockholm, Sweden. 13-14 Mar 2003.
108. **Cohen D**. Evaluation of the enterotoxigenic E. coli killed vaccine in Israeli volunteers [invited lecture]. In: WHO Meeting on "Future directions for research on ETEC vaccines for developing countries". Montreux, Switzerland. 24-25 Mar 2003.
109. **Cohen D**, Bassal R, Green M. Recent trends in the epidemiology of shigellosis in Israel [invited lecture]. In: Research Fair, Tel Aviv University, Sackler Faculty of Medicine, Israel. 14 Apr 2003.
110. **Cohen D**. Development and evaluation of Shigella and enterotoxigenic E. coli vaccines [invited lecture]. In: Israel Society for Microbiology Fall Workshop on Vaccines, Present and Future. Israel. 27-29 Nov 2003.
111. Tal S, Steinman A, Levi O, Banet C, Malkinson M, Shpigel N, Huerta M, I Grotto, Orr N, **Cohen D**. Regional differences in the level of exposure to WNV in Israel among human and equine populations. In: Annual Meeting of the Israeli Society for Microbiology. Haifa, Israel. 9-10 Feb 2004.
112. Halperin T, Yavzori M, Shohat T, Klement E, Grotto I, Huerta M, **Cohen D**, Orr N. Molecular analysis of noroviruses involved in diarrheal diseases in Israel. In: Annual Meeting of the Israeli Society for Microbiology. Haifa, Israel. 9-10 Feb 2004.

113. Yavzori M, Halperin T, Cohen R, Hasin T, Davidovitz N, **Cohen D**, Orr N. Development of a rapid PCR assay for diagnosis of *Borrelia persica*. In: Annual Meeting of the Israeli Society for Microbiology. Haifa, Israel. 9-10 Feb 2004.
114. Orr N, Klement E, Grotto I, Balicer R, Huerta M, Sela T, Gillis D, **Cohen D**. A Single Dose of Inactivated Hepatitis A Vaccine - Protective Immunity for at Least Three Years. In: The 7th Annual Conference of Vaccine Research. Arlington, VA. 24-26 May 2004.
115. Tal S, Steinman A, Levi O, A. Lichter, Banet C, Malkinson M, Shpigel N, Huerta M, Balicer R, I Grotto, Orr N, **Cohen D**. Regional differences in the level of exposure to WNV in Israel among human and equine populations [invited lecture]. In: The Jerusalem International Symposium on Arthropod-Borne Viral Diseases. Mishkenot Shaananim, Jerusalem, Israel. 21-23 Jun 2004.
116. **Cohen D**. Status of clinical trials with *Shigella* conjugate vaccines [invited lecture]. In: Future Needs and Directions of *Shigella* Vaccines. Geneva, Switzerland. 13-15 Sept 2004.
117. **Cohen D**, Bassal R, Green M. Recent trends in the epidemiology of shigellosis in Israel [invited lecture]. In: Future Needs and Directions of *Shigella* Vaccines. Geneva, Switzerland. 13-15 Sept 2004.
118. Davidovici BB, Green M, Marouni MJ, Bassal R, Levy S, Pimenta J, **Cohen D**. A seroepidemiological study to determine the seroprevalence of antibodies to HSV 1 and HSV 2 in Israel. In: The 28th Annual Meeting of the Israel Society of Dermatology and Venereology. Eilat, Israel. 16-17 Jun 2004.
119. Davidovici BB, Green M, Marouni MJ, Bassal R, Levy S, Pimenta J, **Cohen D**. Seroepidemiology of herpes Simplex virus 1 and 2 infections in Israel. In: Conference on Sexually Transmitted Infections. Myconos, Greece. 7-9 Oct 2004.
120. Davidovici BB, Green M, Marouni MJ, Bassal R, Pimenta J, **Cohen D**. Seroprevalence and correlates of infection with herpes virus 1 and herpes virus 2 in Israel. In: The 4th EDEN-IDEA congress. Venice, Italy. 10-12 Oct 2004.
121. **Cohen D**. Food-borne epidemics: natural occurrence or bioterror attack, how can we know? [invited lecture]. In: International Workshop on Defense to Biological Threats. Beer Sheva, Israel. 1-2 Dec 2004.
122. **Cohen D**, Bassal R Valinsky, Green M and the Israel *Shigella* Laboratory-Based Surveillance Network. Cyclic occurrence of epidemics of shigellosis in Israel [invited lecture]. In: Annual Meeting of the Israeli Center for Diseases Control. Beit Sorasky, Tel Hashomer, Israel. Dec 2004.
123. Valinsky L, Simchoni S, Bassal R, S. Goren, Agmon V, R. Yishai, Green MS, **Cohen D**. Prevalence and correlates of diphtheria toxin antibodies in the Israeli population. In: Annual Meeting of the Israeli Society for Microbiology. Ganei Hatarucha, Analyza, Tel Aviv, Israel. 2-3 Feb 2005.
124. Halperin T, Yavzori M, Cohen R, Hasin T, Davidovitch N, Klement E, Kayouf R, Sela T, Ambar R, **Cohen D**, Orr N. Determination of genetic variability among *Borellia persica* identified in patients with relapsing fever in Israel. In: Annual Meeting of the Israeli Society for Microbiology. Ganei Hatarucha, Analyza, Tel Aviv, Israel. 2-3 Feb 2005.

125. Muhsen K, Athamna A, Athamna M, Spungin-Bialik A, **Cohen D**. Prevalence and risk factors of *Helicobacter pylori* infection among healthy 3-5 year-old Israeli Arab children. In: Research Fair at Tel Aviv University, Sackler Faculty of Medicine, Israel. Apr 2005.
126. Davidovici BB, Green M, Marouni MJ, Bassal R, Pimenta J, **Cohen D**. Seroprevalence and correlates of infection with herpes virus 1 and herpes virus 2 in Israel. In: Research Fair at Tel Aviv University, Sackler Faculty of Medicine, Israel. Apr 2005.
127. **Cohen D**. Studies on shigellosis and *Shigella* vaccines [invited lecture]. In: Tel Aviv University Institute Pasteur Workshops: Neuroscience, Cells, and Infection. 10-11 Apr 2005.
128. **Cohen D**. Foodborne Outbreaks Caused by Natural or Intentional Contamination – How Can We Know? [invited lecture]. In: NATO Advanced Research Workshop on “Risk Assessment and Risk Communication Related to Bioterrorism”. Ein Gedi, Israel. 8-11 Jun 2005.
129. **Cohen D**, Bassal R, Valinsky L, Green M and the Israel *Shigella* Laboratory-Based Surveillance Network. Cyclic occurrence of epidemics of shigellosis in Israel [invited lecture]. In: Annual Meeting of the Israel Society for Microbiology. Ben Gurion University, Beer Sheva, Israel. Feb 2006.
130. **Cohen D**, Davidovici BB. The potential impact of global warming on morbidity [invited lecture]. In: Annual National Conference of the Ministry of Environment. Tel Aviv, Israel. 21 June 2006.
131. Tal S, Steinman A, Banet-Noach C, Lichter A, Levi O, Malkinson M, Perk, Shpigel S, **Cohen D**. Seroprevalence and correlates of West Nile Virus antibodies among horses in Israel [invited lecture]. In: The 2nd Jerusalem Symposium on Arthropod-Borne Viral Diseases. Mitzpe Haymim, Israel. 25-30 Jun 2006.
132. **Cohen D**. Enhanced surveillance system for detection and management of infectious diseases in the Middle East [invited lecture]. In: Middle East Frontiers of Science and Engineering. Seville, Spain. 19-21 Marc 2007.
133. **Cohen D**. Studies on shigellosis and *Shigella* vaccines [Sarov Prize lecture]. In: Annual Meeting of the Israel Society for Microbiology. Bar Ilan University, Israel. 19-20 Feb 2007.
134. **Cohen D**, Bassal R, Valinsky L, Vasilev V, Green M. Cyclic occurrence of *S. sonnei* epidemics in Israel. In: International Meeting on Emerging Diseases and Surveillance. Vienna, Austria. 23-25 Feb 2007.
135. Athamna A, Muhsen K, Athamna M, Roth D, Spungin-Bialik A, Halperin T, **Cohen D**. Carriage of quinolone-resistant *Escherichia coli* among healthy Israeli Arab children attending day care centers in Northern Israel. In: The 17th European Congress of Clinical Microbiology and Infectious Diseases. Munchen, Germany. 31 Mar-4 Apr 2007.
136. Flahault A, Carmeli B, **Cohen D**, Ram R, Valleron AJ. Two models for public health interoperability (infectious disease). In: The 12th International Health (Medical) Informatics Congress. Medinfo. Brisbane, Australia. 20-24 Aug 2007.
137. **Cohen D**. Experience in establishing similar traceability mechanisms: Middle East Consortium on Infection Disease Surveillance (MECIDS) [invited lecture]. In: WHO Technical Consultation Development of a WHO Influenza Virus Traceability Mechanism. Ottawa, Canada. 24-26 Sept 2008.

138. Muhsen K, Athamna A, Athamna M, **Cohen D**. Prevalence and Correlates of Giardia lamblia carriage in young Israeli Arab children [abstract]. In: Israeli Society for Parasitology Protozoology and Tropical Diseases. Annual Meeting and Workshop on Intestinal Parasite. 2008: p.38-39. Ramat Gan, Israel. 17-18 Dec 2008.
139. Muhsen K, Shulman L, Rubinstein U, Kasem E, Kremer A, Goren S, Zilberstein I, Ephros M, **Cohen D**. Preliminary data from a hospital-based surveillance network of Rotovirus-associated gastroenteritis in Israel [abstract RVN8]. In: Seventh International Conference of the Society for Free Radical Research-Africa, 28th African Health Science Congress, 4th African Rotavirus Symposium. University of Mauritius. 2008: pg 67. 14-17 Jul 2008.
140. **Cohen D**. Evaluation of the introduction of rotavirus universal vaccination among Israeli infants [invited lecture]. University of Haifa, Haifa, Israel. 28 Feb 2012.
141. Bassal R, Supino Rosin L, Schwimer M, Schejter E, Ozeryansky b, Kulik S, Bachar R, Shapira H, Sandbank J, **Cohen D**, Keinan-Boker L. Prevalence and Correlates of Human Papillomavirus among Patients with Cervical Cancer and Cervical Intraepithelial Neoplasia 3 (CIN3) in Israel. Annual Conference of the Association of Public Health Physicians and Schools of Public Health in Israel: "Health Knows No Borders". Ramat Gan, Israel. 1 June 2015.
142. Bassal R, Ovadia A, Bromberg M, Stein M, Shainberg B, Loewenthal S, Somekh E, **Cohen D**, Shohat T. Risk Factors for Sporadic Infection with Campylobacter SPP Among Children in Israel: A Case Control Study [Poster Presentation]. Annual Conference of the Association of Public Health Physicians and Schools of Public Health in Israel: "Health Knows No Borders". Ramat Gan, Israel. 1 June 2015.
143. Muhsen, K, Goren S, **Cohen D**. Helicobacter pylori infection in early childhood and growth at school age [poster]. The 8th International Conference on Vaccines For Enteric Diseases, The Royal College of Physicians of Edinburgh, Edinburgh, UK. 8-10 Jul 2015.
144. **Cohen D**, Meron-Sudai S, Bialik A, Goren S, Hochberg A, Rubinstein U, Levy O, Bassal R, Ashkenazi S. Agent and host-related factors supporting the global emergence of S. sonnei shigellosis. Vaccines for Enteric Diseases, Edinburgh, Scotland, 8–10 July 2015.
145. Gerke C, Martin L, Loulergue P, Launay O, Lewis D, Greenwood A, **Cohen D**, Saul A, Podda A. Safety and immunogenicity of a Shigella sonnei generalized modules for membrane antigens (GMMA) vaccine administered by intramuscular, intranasal, and intradermal route [poster]. The 8th International Conference on Vaccines for Enteric Diseases, The Royal College of Physicians of Edinburgh, Edinburgh, UK. 8-10 Jul 2015.
146. **Cohen D**, Meron-Sudai S, Bialik A, Dorman A, Goren S, Hochberg A, Rubinstein U, Ashkenazi S. Characterization of the immune response to *Shigella* following natural infection towards identification of correlates of protection. Vaccines Against *Shigella* and ETEC (VASE) Conference. Washington DC, USA. 8-10 June 2016.
147. Bassal R, Avramovich E, Hartal M, Grotto I, **Cohen D**, Shohat T. Middle East Program for Interventional Epidemiology Training (MEPIET). Annual Conference of the Association of Public Health Physicians and Schools of Public Health in Israel. Ramat Gan, Israel. 6 June 2016.
148. Bassal R, Barak M, Ben-Dor A, Amichay D, Bar-Haim A, Shinhar E, **Cohen D**, Shohat T. The national serum bank for population-based seroprevalence studies in Israel. Annual

Conference of the Association of Public Health Physicians and Schools of Public Health in Israel. Ramat Gan, Israel. 6 June 2016.

149. Na'amnih W, Miller-Roll T, **Cohen D**, Carmeli D, Adler A. Molecular types and antimicrobial susceptibility patterns of *Clostridium difficile* isolates in different epidemiological settings in a tertiary care center in Israel. Annual Conference of the Association of Public Health Physicians and Schools of Public Health in Israel. Ramat Gan, Israel. 5 June 2017.
150. Bassal R, Shohat T, Kaufman Z, Menasse B, Shinar E, Amichay D, Barak M, Ben-Dor A, Bar Haim A, **Cohen D**, Mendelson E, Lustig Y. Seroepidemiology of West Nile Virus in Israel: A nationwide cross sectional study. Annual Conference of the Association of Public Health Physicians and Schools of Public Health in Israel. Ramat Gan, Israel. 5 June 2017.
151. Rouach V, Goldshtein I, Wolf I, Catane R, Chodick G, Stern N, **Cohen, D**. Alendronate Reduces the Risk of Bone Metastases in Osteoporotic Women with Early Breast Cancer. Research Exhibition. Tel Aviv, Israel. 28 March 2017.
152. Beer-Davidson G, Hindiyeh M, **Cohen D**, Muhsen K. Detection of *Helicobacter pylori* in stool samples of children using real-time quantitative Polymerase Chain Reaction (q-PCR) assay. Israel Society of Microbiology Meeting. Vulcani Institute, Israel. 6 April 2017.
153. Behar A, Baker KS, Bassal R, Valinsky L, Thomson NR, **Cohen D**. Microevolution and patterns of *Shigella sonnei* transmission within cyclic outbreaks of shigellosis in Israel. Israel Society of Microbiology Meeting. Vulcani Institute, Israel. 6 April 2017.
154. Rouach V, Goldshtein I, Chodick G, Catane R, Wolf I, **Cohen D**. Oral Bisphosphonate exposure and breast cancer disease-free survival in osteoporotic post-menopausal women: Preliminary results. Annual Conference of the Association of Public Health Physicians and Schools of Public Health in Israel. Ramat Gan, Israel. 5 June 2017.
155. **Cohen D**, Atsmon J, Artaud C, Meron-Sudai S, Gougeon M-L, Bialik A, Goren S, Asato A, Ariel-Cohen O, Reizis A, Dorman A, Volokhov I, Shaikevich D, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard L A, Phalipon A. A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of SF2a-TT15, a Synthetic Carbohydrate-Based Conjugate Vaccine against *S. flexneri* 2a in Healthy Adult Volunteers. Vaccine for Enteric Diseases Conference, Ablufeira, Portugal, 9-11 Oct. 2017
156. Sheikh Ali, Bassal R, Abdul-Hai A, Ramlawi A, Abdeen Z, Haddadin A, Al-Abdallat MM, Abdalla S, Alqaseer A, Dichtiar R, Glatman-Freedman A, Shohat T, **Cohen D**. Seroepidemiological study to identify Middle East Respiratory Syndrome Corona Virus (MERS-coV) transmission in Jordan, Israel and Palestinian Authority. CORDS Meeting, PMAC Annual Conference, Bangkok, Thailand January 29-30, 2018.
157. **Cohen D**, Atsmon J, Artaud C, Meron-Sudai S, Gougeon M-L, Bialik A, Goren S, Asato A, Ariel-Cohen O, Reizis A, Dorman A, Volokhov I, Shaikevich D, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard L A, Phalipon A. A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of SF2a-TT15, a Synthetic Carbohydrate-Based Conjugate Vaccine against *S. flexneri* 2a in Healthy Adult Volunteers. 2nd VASE Conference, Mexico City, June 12-14, 2018
158. Danquah L, Sulo J, Mersini K, Bino S, Huda N, Adisasmito W, Soebandrio A, Karimuribo ED, Sindato C, Beda E, Rweyemamu M, Were W, Lutwama JJ, Yishai R, **Cohen D**, Thajeen J, Nyein SL, Oo MK, Libel M, Gresham L, Japra N, Burke C, Orefuwa E, Asquith P, Longuet

- C. Assessment of event based surveillance in cross border areas of six regional networks. [Abstract] in: International Journal of Infectious Diseases. 2019;79:36.
159. Muhsen K, Reshef L, Ornoy A, Maya M, Gophna U, **Cohen D**. Gut microbiota at school age: Influential factors and associations with cognitive development: Preliminary results. [Abstract] in: Helicobacter. 2019;24:1.
160. **Cohen D**. Estimating a threshold level of serum IgG anti-Shigella sonnei LPS associated with protection against S. sonnei shigellosis. Vaccine for Enteric Diseases Conference. Lausanne 16-18 October, 2019
161. Chisenga CC, Bosomprah S, Simuyandi M, Mwila-Kazimbaya K, Chilyabanyama ON, Laban NM, **Cohen D**, Frankel GM, Chilengi R. Shigella-specific antibodies in the first year of life and implications for vaccination among Zambian infants. Vaccine for Enteric Diseases Conference. Washington, USA. 29 November- December 1 2022.
162. Miti S, Chilyabanyama NO, Chisenga CC, Chibuye M, Bosomprah S, Mumba C, Chitondo S, Siziya S, **Cohen D**, Chilengi R, Simuyandi M. Sensitivity and predictive value of dysentery in diagnosing shigellosis among under five children in Zambia. Vaccine for Enteric Diseases Conference. Washington, USA. 29 November- December 1 2022.
163. Miti S, Simuyandi M, Ilubala I, Chilyabanyama NO, Chisenga CC, Chibuye M, Mumba C, Chitondo S, Chakopo M, Meron-Sudai S, Asato V, Siziya S, Chilengi R, **Cohen D**. Prevalence, incidence, clinical presentation, and immune response to Shigella of laboratory-confirmed cases of shigellosis in children under 5 admitted to a children tertiary hospital, Ndola, Zambia (Preliminary data). Vaccine for Enteric Diseases Conference. Washington, USA. 29 November- December 1 2022.
164. Meron-Sudai S, Asato V, Adler A, Bialik A, Goren S, Ariel-Cohen O, Reizis A, Phalipon A, Mulard LA, **Cohen D**. Longevity of the immune response to the synthetic carbohydrate-based conjugate vaccine candidate SF2a-TT15 in adult volunteers two and three years after vaccination. Vaccine for Enteric Diseases Conference. Washington, USA. 29 November- December 1 2022.
165. Asato V, Meron-Sudai S, Bialik A, Goren S, Bassal R, MacLennan CA, **Cohen D**. IgG antibody levels to S. sonnei LPS and incidence of culture-proven S. sonnei shigellosis in Israeli children and adolescents. Vaccine for Enteric Diseases Conference. Washington, USA. 29 November- December 1 2022.
166. **Cohen D**, Ashkenazi S, Schneerson R, Farzam N, Bialik A, Meron-Sudai S, Asato V, Goren S, Ziv Baran T, Muhsen K, Gilbert P, MacLennan C. Threshold levels of serum IgG to Shigella lipopolysaccharide can predict degrees of vaccine efficacy in field trials and serve as a substitute endpoint for protection against shigellosis. Vaccine for Enteric Diseases Conference. Washington, USA. 29 November- December 1 2022.